Method for Producing N6-((2-Azidoethoxy)carbonyl)Lysine

A solvent-based method for producing N6-((2-azidoethoxy)carbonyl)lysine addresses yield and safety issues in traditional production methods by using acids and alkali azide salts in controlled solvent environments.

JP7579344B2Active Publication Date: 2024-11-07SYNTHORX INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2022537424
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-12-23
Filing Date
2020-12-22
Publication Date
2024-11-07
Estimated Expiration
2040-12-22

AI Technical Summary

Technical Problem

Existing methods for producing N6-((2-azidoethoxy)carbonyl)lysine rely on chemical intermediates that result in poor yields and pose safety risks.

Method used

A method involving the reaction of compounds with acids and alkali azide salts in specific solvents to produce N6-((2-azidoethoxy)carbonyl)lysine, utilizing aprotic and protic solvents to enhance yield and safety.

Benefits of technology

The method provides a reproducible and high-yield production of N6-((2-azidoethoxy)carbonyl)lysine, reducing safety risks associated with traditional chemical intermediates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579344000160
    Figure 0007579344000160
  • Figure 0007579344000161
    Figure 0007579344000161
  • Figure 0007579344000162
    Figure 0007579344000162
Patent Text Reader

Abstract

Disclosed herein is a method for producing a medicament comprising: 6 -((2-azidoethoxy)carbonyl)lysine, N 6 -((2-azidoethoxy)carbonyl)-L-lysine, and N 6 Further disclosed herein is a method for producing the compound tert-butyl N-((2-azidoethoxy)carbonyl)-D-lysine. 2 -(tert-butoxycarbonyl)-N 6 -((2-chloroethoxy)carbonyl)-L-lysinate and tert-butyl N 6 -((2-azidoethoxy)carbonyl)-N 2 -(tert-butoxycarbonyl)-L-lysinate, and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 953,089, filed December 23, 2019, the disclosure of which is incorporated herein by reference in its entirety. [Background technology]

[0002] Compound N 6 -((2-azidoethoxy)carbonyl)lysine and its two enantiomers, N 6 -((2-azidoethoxy)carbonyl)-L-lysine and N 6 -((2-azidoethoxy)carbonyl)-D-lysine is useful in the production of polypeptides and proteins as research tools and therapeutic products. For example, the orthogonal Methanosarcina barkeri MS pyrrolysyl-tRNA synthetase / tRNA pair synthesizes N-terminal lysine into recombinant proteins in Escherichia coli. 6 It has been demonstrated that efficient site-specific incorporation of -((2-azidoethoxy)carbonyl)-L-lysine can be induced. Proteins containing azide functional groups can be coupled via a [3+2] cycloaddition reaction to attach fluorescent labels and other functional moieties to the protein. N-((2-azidoethoxy)carbonyl)-L-lysine, which contains two enantiomers, can be synthesized using the same method. 6 Conventional methods for the production of -((2-azidoethoxy)carbonyl)lysine have poor yields or rely on chemical intermediates that may pose significant safety hazards (Non-Patent Document 1; Patent Document 1). Thus, there is a need for reproducible, high-yield methods for the production of these compounds that rely on the production of chemical intermediates that can reduce safety hazards. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] US Patent Application Publication No. 2016 / 0297855 [Non-patent literature]

[0004] [Non-Patent Document 1] Milles, S. et al., J. Am. Chem. Soc. (2012), 134, 5187-5195 Summary of the Invention [Means for solving the problem]

[0005] Described herein, in certain embodiments, is a method for producing a medicament comprising administering to a subject a compound comprising: 6 A process for preparing .alpha.-((2-azidoethoxy)carbonyl)lysine and intermediates useful therein.

[0006] The following embodiments are included:

[0007] Embodiment 1 is a compound of formula (VI) [ka] or a salt thereof, comprising the steps of:

[0008] To obtain a compound of formula (VI) or a salt thereof, [ka] with an acid.

[0009] Embodiment 2 is the method of embodiment 1, wherein the acid is one or more of phosphoric acid, hydrochloric acid, acetic acid, and trifluoroacetic acid.

[0010] Embodiment 3 is the method of embodiment 1 or 2, wherein the acid is hydrochloric acid.

[0011] Embodiment 4 is the method of any one of embodiments 1 to 3, wherein the reaction of the compound of Formula (III) with the acid is carried out in a solution comprising an aprotic solvent selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG 400, and polyethylene glycols.

[0012] Embodiment 5 is the method of embodiment 4, wherein the aprotic solvent is 1,4-dioxane.

[0013] Embodiment 6 is the method of any one of embodiments 1 to 5, further comprising the addition of a base.

[0014] Embodiment 7 is the method of embodiment 6, wherein the base is one or more of ammonium hydroxide, sodium hydroxide, or potassium hydroxide.

[0015] Embodiment 8 is the method of embodiment 6 or 7, wherein the base is ammonium hydroxide.

[0016] Embodiment 9 is the method of any one of embodiments 6 to 8, wherein the addition of base provides a solution having a pH in the range of 4 to 10.

[0017] Embodiment 10 is the method of any one of embodiments 6 to 9, wherein the addition of base provides a solution having a pH in the range of 8 to 9.

[0018] In an embodiment 11, the compound of formula (VI) is represented by the formula (VIa) [ka] The method according to any one of embodiments 1-10, wherein the compound is

[0019] Embodiment 12 is a compound of formula (III) [ka] The method for preparing a compound of formula (III) comprises the steps of: [ka] (In the formula, R 1 is selected from chloro, bromo, and iodo. with an alkali azide salt.

[0020] Embodiment 13 is a compound comprising R 1 The method of embodiment 12, wherein

[0021] Embodiment 14 is the method of embodiment 12 or 13, wherein the alkali azide salt is selected from lithium azide, sodium azide, and potassium azide.

[0022] Embodiment 15 is the method of any one of embodiments 12-14, wherein the alkali azide salt is sodium azide.

[0023] Embodiment 16 is the method of any one of embodiments 12 to 15, wherein the reaction of the compound of Formula (II) with the alkali azide salt is carried out in a solution comprising an aprotic solvent selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG 400, and polyethylene glycols.

[0024] Embodiment 17 is the method of embodiment 16, wherein the aprotic solvent is acetonitrile.

[0025] Embodiment 18 is the method of embodiment 16 or 17, wherein the solution further comprises water.

[0026] In embodiment 19, the compound of formula (III) is represented by the formula (IIIa) [ka] and the compound of formula (II) is a compound of formula (IIa) [ka] 19. The method according to any one of embodiments 12-18, wherein the compound is

[0027] Embodiment 20 is a compound of formula (II) [ka] A method for preparing a compound of formula (I) to obtain a compound of formula (II) [ka] With a compound of formula (V) [ka] with a compound of wherein in each of the compounds of formula (I) and formula (II), R 1 are the same and are selected from chloro, bromo and iodo.

[0028] Embodiment 21 relates to R in each of the compounds of formula (I) and formula (II). 1 21. The method of embodiment 20, wherein

[0029] Embodiment 22 is the method of embodiment 20 or 21, wherein the reaction of the compound of Formula (V) with the compound of Formula (I) is carried out in a solution comprising an aprotic solvent selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG 400, and polyethylene glycols.

[0030] Embodiment 23 is the method of embodiment 22, wherein the aprotic solvent is 2-methyltetrahydrofuran or N,N-dimethylformamide.

[0031] In embodiment 24, the compound of formula (II) is represented by the formula (IIa) [ka] The compound of formula (V) is a compound of formula (Va) [ka] 24. The method according to any one of embodiments 20-23, wherein the compound is

[0032] Embodiment 25 is a compound of formula (I) [ka] A method for preparing a compound of formula (I), comprising the steps of: [ka] with N-hydroxysuccinimide, wherein in each of the compounds of formula (I) and formula (IV), R 1are the same and are selected from chloro, bromo, and iodo.

[0033] Embodiment 26 is a method for producing a compound according to the present invention 1 26. The method of embodiment 25, wherein

[0034] Embodiment 27 is the method of embodiment 25 or 26, wherein the reaction of the compound of formula (IV) with N-hydroxysuccinimide is carried out in a solution comprising an aprotic solvent selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG 400, and polyethylene glycols.

[0035] Embodiment 28 is the method of embodiment 27, wherein the aprotic solvent is acetonitrile or 2-methyltetrahydrofuran.

[0036] Embodiment 29 is the method of embodiment 27 or 28, wherein the solution further comprises a base.

[0037] Embodiment 30 is the method of embodiment 29, wherein the base is a trialkylamine.

[0038] Embodiment 31 is the method of embodiment 29 or 30, wherein the base is triethylamine.

[0039] Embodiment 32 is a method for preparing a compound of formula (VIa), or a salt thereof, comprising the steps of: (i) [ka] To form [ka] of [ka] and reacting with;

[0040] (ii) [ka] To form [ka] of [ka] and reacting with;

[0041] (iii) [ka] To form [ka] reacting with NaN3;

[0042] (iv) [ka] or to form a salt thereof [ka] Reacting with HCl The method includes:

[0043] Embodiment 33 relates to a compound of formula (I): [ka] (In the formula, R 1 is selected from chloro, bromo, and iodo. It is a compound of the formula:

[0044] Embodiment 34 is directed to R 1 and R is chloro.

[0045] Embodiment 35 relates to a compound of formula (II): [ka] (In the formula, R 1 is selected from chloro, bromo, and iodo. It is a compound of the formula:

[0046] Embodiment 36 is directed to R 1 and R is chloro.

[0047] In embodiment 37, the compound of formula (II) has the formula (IIa): [ka] 37. The compound of embodiment 35 or 36, wherein

[0048] Embodiment 38 relates to a compound of formula (III): [ka] It is a compound of the formula:

[0049] In embodiment 39, the compound of formula (III) has the formula (IIIa): [ka] The compound according to embodiment 38 is a compound of the formula:

[0050] Embodiment 40 relates to a compound of formula (VII): [ka] (In the formula: R 3 is selected from chloro, bromo and iodo; R 4 -OR 6 , -CF3, -CH2C6~C 12 aryl, and C1-C6 alkyl; R 5 is -CH2C6~C 12 aryl or C1-C6 alkyl; R 6 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 aryl) It is a compound of the formula:

[0051] Embodiment 41 relates to a compound of formula (VIII): [ka] (In the formula: R 7 -OR 9 , -CF3, -CH2C6~C 12 aryl, and C1-C6 alkyl; R 8 is -CH2C6~C 12 aryl or C1-C6 alkyl; R 9 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 aryl) It is a compound of the formula:

[0052] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings, in which: [Brief description of the drawings]

[0053] [Figure 1]FIG. 1 shows a plot of self-heating and pressure versus temperature of N6-((2-azidoethoxy)carbonyl)-N2-(tert-butoxycarbonyl)-L-lysinate (Formula (IIIa)) for the ARC study described in Example 10. [Diagram 2] FIG. 1 shows a graph of temperature and pressure versus time for N6-((2-azidoethoxy)carbonyl)-N2-(tert-butoxycarbonyl)-L-lysinate (Formula (IIIa)) for the ARC study described in Example 10. [Diagram 3] FIG. 1 shows the Antoine plot of N6-((2-azidoethoxy)carbonyl)-N2-(tert-butoxycarbonyl)-L-lysinate (Formula (IIIa)) for the ARC study described in Example 10. [Figure 4] FIG. 1 shows the time to maximum rate plot of N6-((2-azidoethoxy)carbonyl)-N2-(tert-butoxycarbonyl)-L-lysinate (Formula (IIIa)) for the ARC study described in Example 10. [Diagram 5] FIG. 1 shows a plot of time (log scale) versus temperature of N6-((2-azidoethoxy)carbonyl)-N2-(tert-butoxycarbonyl)-L-lysinate (Formula (IIIa)) for the ARC study described in Example 10. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0054] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. It should be understood that the detailed description is merely exemplary and explanatory and does not limit any claimed subject matter. In this application, the use of the singular includes the plural unless specifically stated otherwise. It should be noted that as used herein, the singular forms "a", "an" and "the" include plural referents unless otherwise clearly indicated by the context. In this application, the use of "or" means "and / or" unless specifically stated otherwise. Furthermore, the use of the term "including" as well as other forms such as "include", "includes" and "included" is not limiting.

[0055] Although various features of the invention may be described in the context of a single embodiment, the features may also be provided separately or in any suitable combination. Conversely, although the invention may be described herein for clarity in the context of separate embodiments, the invention may also be practiced in a single embodiment.

[0056] References herein to "some embodiments," "an embodiment," "one embodiment," or "other embodiments" mean that a particular configuration, structure, or feature described in connection with an embodiment is included in at least some, but not necessarily all, embodiments of the present disclosure.

[0057] As used herein, ranges and amounts may be expressed as "about" a particular value or range. About includes the exact amount. Thus, "about 0°C" means "about 0°C" as well as "0°C". In general, the term "about" includes amounts that are expected to be within experimental error, such as within 15%, 10%, or 5%.

[0058] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0059] The term "C1-C6 alkyl" as used herein refers to a group of the formula C having 1 to 6 carbon atoms and which may be linear or branched. n H 2n+1 Examples of such groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, and hexyl.

[0060] "C6~C 12 The term "aryl" as used herein means an aromatic monocyclic or bicyclic hydrocarbon containing 6 to 12 ring carbon atoms bonded through one of the ring carbon atoms. 12 When aryl is substituted, the substituent is located on the ring carbon atom.Specific examples include, but are not limited to, phenyl, tolyl, xylyl, trimethylphenyl, and naphthyl.Examples of aryl substituents include, but are not limited to, alkyl, hydroxyl, halo, nitrile, alkoxy, trifluoromethyl, carboxamide, SO2CH3, benzyl, and substituted benzyl.

[0061] Although various features of the invention may be described in the context of a single embodiment, the features may also be provided separately or in any suitable combination. Conversely, although the invention may be described herein for clarity in the context of separate embodiments, the invention may also be practiced in a single embodiment.

[0062] Compounds and methods of preparation Compounds of formula (I) Described herein is a compound of formula (I) [ka] (In the formula, R1 is selected from chloro, bromo, and iodo. 1 is chloro. In some embodiments, R 1 is bromo. In some embodiments, R 1 is iodine.

[0063] CR of the compound of formula (I) 1 Bond (where R 1 is chloro, bromo, or iodo) is sufficiently reactive to allow further reaction, for example with a compound of formula (V). In some embodiments, a compound of formula (I) is reacted with a fluoro analog, such as with a compound of formula (V) to form a compound of formula (II). [ka] (WO 2012 / 019299). In some embodiments, the reaction rate of the compound of formula (I) with the compound of formula (V) to form the compound of formula (II) is faster than the reaction rate of the corresponding fluoro analogue. In some embodiments, the reaction rate of the compound of formula (I) with the compound of formula (V) to form the compound of formula (II) is more useful in chemical synthesis than the reaction rate using the corresponding fluoro analogue.

[0064] Compounds of formula (I) can be prepared using starting materials that are either commercially available or readily available by methods known to those skilled in the art. For example, R 1Compounds of formula (I) where is chloro can be prepared by reacting 2-chloroethyl chloroformate with N-hydroxysuccinimide, either of which are commercially available or can be prepared by methods known to those skilled in the art. The reaction of 2-chloroethyl chloroformate with N-hydroxysuccinimide can be carried out in a solution containing an aprotic solvent such as acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG 400, and polyethylene glycols. In some embodiments, the aprotic solvent that can be used is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane. In other embodiments, the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, and N,N-dimethylformamide. In yet another embodiment, the aprotic solvent is acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, or tetrahydrofuran. In some embodiments, the aprotic solvent that can be used is 2-methyltetrahydrofuran. The solution in which the 2-haloethyl chloroformate is reacted with N-hydroxysuccinimide may further include a base, which may include an organic base or an inorganic base, or both an organic base and an inorganic base. In some cases, the organic base used may be selected from a heterocyclic base and a trialkylamine, or a mixture thereof.Furthermore, when a heterocyclic base is used, it can be selected from an aromatic heterocyclic base or a non-aromatic heterocyclic base, or a mixture of aromatic heterocyclic base and non-aromatic heterocyclic base. Examples of aromatic heterocyclic bases include, but are not limited to, pyridine, 1-alkylpyrrole, and 1-alkylimidazole, or a mixture thereof. Further examples of aromatic heterocyclic bases that can be used include pyridine, 1-methylpyrrole, and 1-methylimidazole, or a mixture thereof. In some cases, the heterocyclic base used can be a non-aromatic heterocyclic base, including, but not limited to, N-alkylpyrrolidine, N-alkylpiperidine, N-alkylmorpholine, and 1,4-dialkylpiperazine, or a mixture thereof. Further examples of non-aromatic heterocyclic bases that can be used include, but are not limited to, N-methylpyrrolidine, N-methylpiperidine, and N-methylmorpholine. In other cases, one skilled in the art can use a base that is a trialkylamine, examples of which include, but are not limited to, trimethylamine, triethylamine, tri-n-propylamine, tri-n-butylamine, tripentylamine, trihexylamine, and diisopropylethylamine. In some embodiments, the base is triethylamine. The reaction of the 2-haloethyl chloroformate compound with N-hydroxysuccinimide can further be carried out at a temperature in the range of about -25°C to about 100°C, or in the range of about 0°C to about room temperature. In some embodiments, the reaction is carried out at a temperature of about 0°C. In the above embodiments and any embodiments described herein in which an aprotic solvent is used, the reaction solvent is substantially free or free of protic solvents. "Substantially free" means that the referenced substance is not present or is present in a sufficiently small amount that its effect on the reaction is negligible (e.g., less than a 15%, 10%, or 5% effect on the yield of the reaction).

[0065] Formula (I) (wherein, R 1One example of a method that can be used to prepare a compound of formula (I) is chloro is shown in Scheme 1 below.

[0066] [ka]

[0067] R using 2-bromoethyl chloroformate or 2-iodomethyl chloroformate, respectively. 1 A similar method can be used to prepare compounds of formula (I) where is bromo or iodo. The compound 2-bromoethyl chloroformate is commercially available or can be prepared by methods known to those skilled in the art. The preparation of 2-iodomethyl chloroformate is described in Grimshaw et al., Journal of the Chemical Society, 1965, pp. 7136-9.

[0068] In one embodiment, provided herein is a compound of formula (I): [ka] A method for preparing a compound of formula (I), comprising the steps of: [ka] with N-hydroxysuccinimide, wherein in each of the compounds of formula (I) and (IV), R 1 are the same and are selected from chloro, bromo, and iodo. 1 In some embodiments of the method, R 1 In some embodiments of the method, R 1 is iodine.

[0069] In some embodiments of the method of preparing a compound of formula (I) disclosed herein, the reaction of the compound of formula (IV) with N-hydroxysuccinimide is carried out in a solution containing an aprotic solvent. In some embodiments, the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols. In some embodiments, the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane. In some embodiments, the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, and N,N-dimethylformamide. In some embodiments, the aprotic solvent is acetonitrile. In some embodiments, the aprotic solvent is acetone. In some embodiments, the aprotic solvent is methyl ethyl ketone. In some embodiments, the aprotic solvent is dichloromethane. In some embodiments, the aprotic solvent is chloroform. In some embodiments, the aprotic solvent is tetrahydrofuran. In some embodiments, the aprotic solvent is 2-methyltetrahydrofuran. In some embodiments, the aprotic solvent is N,N-dimethylformamide.

[0070] In some embodiments, the solution further comprises a base. In some embodiments, the base is selected from an organic base and an inorganic base. In some embodiments, the organic base is selected from a heterocyclic base and a trialkylamine, or a mixture thereof. In some embodiments, the heterocyclic base is an aromatic heterocyclic base or a non-aromatic heterocyclic base, or a mixture of an aromatic heterocyclic base and a non-aromatic heterocyclic base. In some embodiments, the heterocyclic base is an aromatic heterocyclic base. In some embodiments, the aromatic heterocyclic base is selected from pyridine, 1-alkylpyrrole, and 1-alkylimidazole, or a mixture thereof. In some embodiments, the aromatic heterocyclic base is selected from pyridine, 1-methylpyrrole, and 1-methylimidazole, or a mixture thereof. In some embodiments, the aromatic heterocyclic base is pyridine. In some embodiments, the aromatic heterocyclic base is 1-methylpyrrole. In some embodiments, the aromatic heterocyclic base is 1-methylimidazole. In some embodiments, the heterocyclic base is a non-aromatic heterocyclic base. In some embodiments, the non-aromatic heterocyclic base is selected from N-alkylpyrrolidine, N-alkylpiperidine, N-alkylmorpholine, and 1,4-dialkylpiperazine, or a mixture thereof. In some embodiments, the non-aromatic heterocyclic base is N-alkylpyrrolidine. In some embodiments, the non-aromatic heterocyclic base is N-alkylpiperidine. In some embodiments, the non-aromatic heterocyclic base is N-alkylmorpholine. In some embodiments, the non-aromatic heterocyclic base is 1,4-dialkylpiperazine. In some embodiments, the non-aromatic heterocyclic base is selected from N-methylpyrrolidine, N-methylpiperidine, and N-methylmorpholine. In some embodiments, the non-aromatic heterocyclic base is N-methylpyrrolidine. In some embodiments, the non-aromatic heterocyclic base is N-methylpiperidine. In some embodiments, the non-aromatic heterocyclic base is N-methylmorpholine.In some embodiments, the organic base is a trialkylamine. In some embodiments, the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, tri-n-butylamine, tripentylamine, trihexylamine, and diisopropylethylamine. In some embodiments, the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, and diisopropylethylamine. In some embodiments, the trialkylamine is selected from triethylamine, tri-n-propylamine, and diisopropylethylamine. In some embodiments, the trialkylamine is triethylamine or diisopropylethylamine. In some embodiments, the trialkylamine is triethylamine. In some embodiments, the trialkylamine is diisopropylethylamine.

[0071] In some embodiments of the methods of making a compound of formula (I) disclosed herein, R 1is chloro and the aprotic solvent is acetonitrile. In some embodiments, the solution further comprises a base. In some embodiments, the base is selected from a trialkylamine. In some embodiments, the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, tri-n-butylamine, tripentylamine, trihexylamine, and diisopropylethylamine. In some embodiments, the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, and diisopropylethylamine. In some embodiments, the trialkylamine is selected from triethylamine, tri-n-propylamine, and diisopropylethylamine. In some embodiments, the trialkylamine is triethylamine or diisopropylethylamine. In some embodiments, the trialkylamine is triethylamine. In some embodiments, the trialkylamine is diisopropylethylamine.

[0072] In some embodiments of the methods of making a compound of formula (I) disclosed herein, R 1is bromo and the aprotic solvent is acetonitrile. In some embodiments, the solution further comprises a base. In some embodiments, the base is selected from a trialkylamine. In some embodiments, the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, tri-n-butylamine, tripentylamine, trihexylamine, and diisopropylethylamine. In some embodiments, the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, and diisopropylethylamine. In some embodiments, the trialkylamine is selected from triethylamine, tri-n-propylamine, and diisopropylethylamine. In some embodiments, the trialkylamine is triethylamine or diisopropylethylamine. In some embodiments, the trialkylamine is triethylamine. In some embodiments, the trialkylamine is diisopropylethylamine.

[0073] In some embodiments of the methods of making a compound of formula (I) disclosed herein, R 1is iodine and the aprotic solvent is acetonitrile. In some embodiments, the solution further comprises a base. In some embodiments, the base is selected from a trialkylamine. In some embodiments, the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, tri-n-butylamine, tripentylamine, trihexylamine, and diisopropylethylamine. In some embodiments, the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, and diisopropylethylamine. In some embodiments, the trialkylamine is selected from triethylamine, tri-n-propylamine, and diisopropylethylamine. In some embodiments, the trialkylamine is triethylamine or diisopropylethylamine. In some embodiments, the trialkylamine is triethylamine. In some embodiments, the trialkylamine is diisopropylethylamine.

[0074] Compound of formula (II) Further disclosed herein is a compound of formula (II) [ka] (In the formula, R 1 is selected from chloro, bromo, and iodo. It is a compound of the formula:

[0075] In some embodiments of the compound of Formula (II), R 1 In some embodiments of the compound of Formula (II), R 1 In some embodiments of the compound of Formula (II), R 1 is iodine.

[0076] Further disclosed herein is a compound of formula (IIa) [ka] (In the formula, R 1 is selected from chloro, bromo, and iodo. It is a compound of the formula:

[0077] In some embodiments of the compound of Formula (IIa), R 1 In some embodiments of the compound of Formula (IIa), R 1 In some embodiments of the compound of Formula (IIa), R 1 is iodine.

[0078] Further disclosed herein is a compound of formula (IIb) [ka] (In the formula, R 1 is selected from chloro, bromo, and iodo. It is a compound of the formula:

[0079] In some embodiments of the compound of Formula (IIb), R 1 In some embodiments of the compound of Formula (IIb), R 1 In some embodiments of the compound of Formula (IIb), R 1 is iodine.

[0080] The compound of formula (II) can be reacted with a compound of formula (I) (wherein R 1 is selected from chloro, bromo and iodo [ka] With a compound of formula (V) [ka] In some embodiments, R 1 is chloro. In some embodiments, R 1 is bromo. In some embodiments, R 1is iodine.

[0081] The reaction of the compound of formula (I) with the compound of formula (V) can be carried out in a solution containing an aprotic solvent such as acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethyl sulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG 400, and polyethylene glycols. In some embodiments, the aprotic solvent that can be used is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethyl sulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane. In other embodiments, the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, and N,N-dimethylformamide. In yet another embodiment, the aprotic solvent is acetonitrile, or acetone, or methyl ethyl ketone, or dichloromethane, or chloroform, or tetrahydrofuran. In some embodiments, the aprotic solvent is acetonitrile. In some embodiments, the aprotic solvent is acetone. In some embodiments, the aprotic solvent is methyl ethyl ketone. In some embodiments, the aprotic solvent is dichloromethane. In some embodiments, the aprotic solvent is chloroform. In some embodiments, the aprotic solvent is tetrahydrofuran. In some embodiments, the aprotic solvent is 2-methyltetrahydrofuran. In some embodiments, the aprotic solvent is N,N-dimethylformamide.

[0082] The solution in which the compound of formula (I) is reacted with the compound of formula (V) may further comprise a base, which may comprise an organic base or an inorganic base, or both an organic base and an inorganic base. In some cases, the organic base used may be selected from a heterocyclic base and a trialkylamine, or a mixture thereof. Furthermore, when a heterocyclic base is used, it may be selected from an aromatic heterocyclic base or a non-aromatic heterocyclic base, or a mixture of an aromatic heterocyclic base and a non-aromatic heterocyclic base. Examples of aromatic heterocyclic bases include, but are not limited to, pyridine, 1-alkylpyrrole, and 1-alkylimidazole, or a mixture thereof. Further examples of aromatic heterocyclic bases that may be used include pyridine, 1-methylpyrrole, and 1-methylimidazole, or a mixture thereof. In some cases, the heterocyclic base used can be a non-aromatic heterocyclic base, including but not limited to N-alkylpyrrolidine, N-alkylpiperidine, N-alkylmorpholine, and 1,4-dialkylpiperazine, or mixtures thereof. Further examples of non-aromatic heterocyclic bases that can be used include but are not limited to N-methylpyrrolidine, N-methylpiperidine, and N-methylmorpholine. In other cases, those skilled in the art can use a base that is a trialkylamine, examples of which include but are not limited to trimethylamine, triethylamine, tri-n-propylamine, tri-n-butylamine, tripentylamine, trihexylamine, and diisopropylethylamine. In some embodiments, the base is diisopropylethylamine.

[0083] The reaction of the compound of formula (I) with the compound of formula (V) can further be carried out at a temperature ranging from about −25° C. to about 100° C., or from about 0° C. to about room temperature. In some embodiments, the reaction is carried out at a temperature of about 10° C.

[0084] One example of a method that can be used to prepare a compound of formula (II) is shown in Scheme 2 below.

[0085] [ka]

[0086] Formula (II) (wherein, R 1 One example of a method that can be used to prepare a compound of formula (I) is chloro is shown below in Scheme 3.

[0087] [ka]

[0088] Compounds of formula (IIa) and (IIb) can be prepared using methods similar to those described above by using the L-enantiomer or the D-enantiomer of compound of formula (V) as shown in Scheme 4 and Scheme 5 below.

[0089] [ka]

[0090] Further disclosed herein is a compound of formula (IIa) [ka] A method for preparing a compound of formula (I) comprising the steps of: [ka] The compound of formula (Va) [ka] with a compound of formula R 1 In some embodiments of the method, R 1 In some embodiments of the method, R 1 In some embodiments of the method, R1 is iodine. In some embodiments, the reaction of the compound of formula (Va) with the compound of formula (I) is carried out in a solution containing an aprotic solvent. In some embodiments, the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethyl sulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols. In some embodiments, the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethyl sulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane. In some embodiments, the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, and N,N-dimethylformamide. In some embodiments, the aprotic solvent is acetonitrile. In some embodiments, the aprotic solvent is acetone. In some embodiments, the aprotic solvent is methyl ethyl ketone. In some embodiments, the aprotic solvent is dichloromethane. In some embodiments, the aprotic solvent is chloroform. In some embodiments, the aprotic solvent is tetrahydrofuran. In some embodiments, the aprotic solvent is 2-methyltetrahydrofuran. In some embodiments, the aprotic solvent is N,N-dimethylformamide.

[0091] Further disclosed herein is a compound of formula (IIb) [ka] A method for preparing a compound of formula (I) comprising the steps of: [ka] With a compound of formula (Vb) [ka] with a compound of formula R 1 In some embodiments of the method, R 1 In some embodiments of the method, R 1 In some embodiments of the method, R 1is iodine. In some embodiments, the reaction of the compound of formula (Vb) with the compound of formula (I) is carried out in a solution containing an aprotic solvent. In some embodiments, the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethyl sulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols. In some embodiments, the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethyl sulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane. In some embodiments, the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, and N,N-dimethylformamide. In some embodiments, the aprotic solvent is acetonitrile. In some embodiments, the aprotic solvent is acetone. In some embodiments, the aprotic solvent is methyl ethyl ketone. In some embodiments, the aprotic solvent is dichloromethane. In some embodiments, the aprotic solvent is chloroform. In some embodiments, the aprotic solvent is tetrahydrofuran. In some embodiments, the aprotic solvent is 2-methyltetrahydrofuran. In some embodiments, the aprotic solvent is N,N-dimethylformamide.

[0092] Compounds of formula (V), including the L- and D-enantiomers, are commercially available or can be prepared by methods known to those skilled in the art.

[0093] Compound of formula (III) Further disclosed herein is a compound of formula (III) [ka] It is a compound of the formula:

[0094] In some embodiments, the compound of formula (III) has the formula (IIIa): [ka] It is a compound of the formula:

[0095] In some embodiments, the compound of formula (III) has the formula (IIIb): [ka] It is a compound of the formula:

[0096] The compound of formula (III) can be reacted with a compound of formula (II) (wherein R 1is selected from chloro, bromo, and iodo) with an alkali azide salt. In some embodiments, the alkali azide salt is selected from lithium azide, sodium azide, and potassium azide. In some cases, the alkali azide salt is lithium azide. In other cases, the alkali azide salt is sodium azide. In yet other cases, the alkali azide salt is potassium azide. The reaction of the compound of formula (II) with an alkali azide salt can be carried out in a solution comprising an aprotic solvent, a protic solvent, or a mixture thereof. Aprotic solvents that can be used can be selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethyl sulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols. In some cases, the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N-methylpyrrolidine, dimethyl sulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane. In some embodiments, the aprotic solvent is acetonitrile. In some embodiments, the aprotic solvent is tetrahydrofuran. In some embodiments, the aprotic solvent is 2-methyltetrahydrofuran. In some embodiments, the aprotic solvent is N,N-dimethylformamide. In some embodiments, the aprotic solvent is 1,4-dioxane. In some cases, the reaction of the compound of formula (II) with the alkali azide salt can be carried out in a solution containing a mixture of aprotic solvent and protic solvent, where the aprotic solvent is as described above, and the protic solvent can be selected from water and alcohol. In some embodiments, the protic solvent is water.In some embodiments, the protic solvent is an alcohol. Examples of alcohols that can be used include, but are not limited to, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, n-pentanol, and isopentanol. In some embodiments, the alcohol is selected from methanol, ethanol, n-propanol, and isopropanol. In some cases, the solution may include a mixture of water and 1,4-dioxane. In some cases, the solution may include a mixture of water and acetonitrile. Formula (II) (wherein R. 1 The reaction of the compound (wherein is selected from chloro, bromo, and iodo) with an alkali azide salt can be carried out at a temperature ranging from about 25° C. to about 150° C., or from about 75° C. to about 80° C. In some embodiments, the reaction is carried out at a temperature of about 80° C.

[0097] Reacting with an alkali azide salt of formula (II) (wherein R 1 One example of a method that can be used to prepare a compound of formula (III) by reaction of a compound of formula (III) where R is selected from chloro, bromo, and iodo is shown in Scheme 6 below.

[0098] [ka]

[0099] Formula (II) (wherein, R 1 One example of a method that can be used to prepare a compound of formula (III) by reaction of a compound of formula (III) (wherein R is chloro) and sodium azide is shown below in Scheme 7.

[0100] [ka]

[0101] Compounds of formula (IIIa) and (IIIb) can be prepared using methods similar to those described above by using the L-enantiomer or the D-enantiomer of compound of formula (II) as shown in Scheme 8 and Scheme 9 below.

[0102] [ka]

[0103] Further disclosed herein is a compound of formula (IIIa) [ka] A method for preparing a compound of formula (IIa) comprising the steps of: [ka] (In the formula, R 1is selected from chloro, bromo, and iodo) with an alkali azide salt. In some embodiments, the alkali azide salt is selected from lithium azide, sodium azide, and potassium azide. In some embodiments, the alkali azide salt is lithium azide. In some embodiments, the alkali azide salt is sodium azide. In some embodiments, the alkali azide salt is potassium azide. In some embodiments, the reaction of the compound of Formula (IIa) with an alkali azide salt is carried out in a solution comprising an aprotic solvent, a protic solvent, or a mixture thereof. In some embodiments, the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethyl sulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols. In some embodiments, the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N-methylpyrrolidine, dimethyl sulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane. In some embodiments, the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N,N-dimethylformamide, and 1,4-dioxane. In some embodiments, the aprotic solvent is acetonitrile. In some embodiments, the aprotic solvent is tetrahydrofuran. In some embodiments, the aprotic solvent is 2-methyltetrahydrofuran. In some embodiments, the aprotic solvent is N,N-dimethylformamide. In some embodiments, the aprotic solvent is 1,4-dioxane. In some embodiments, the reaction of the compound of Formula (IIa) with an alkali azide salt is carried out in a solution comprising a mixture of an aprotic solvent and a protic solvent.In some embodiments, the protic solvent is selected from water and an alcohol. In some embodiments, the protic solvent is water. In some embodiments, the protic solvent is an alcohol. In some embodiments, the alcohol is selected from methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, n-pentanol, and isopentanol. In some embodiments, the alcohol is selected from methanol, ethanol, n-propanol, and isopropanol. In some embodiments, the solution comprises a mixture of water and 1,4-dioxane. In some embodiments, the solution comprises a mixture of water and acetonitrile.

[0104] Further disclosed herein is a compound of formula (IIIb) [ka] A method for preparing a compound of formula (IIb) to obtain a compound of formula (IIIb) [ka] (In the formula, R 1is selected from chloro, bromo, and iodo) with an alkali azide salt. In some embodiments, the alkali azide salt is selected from lithium azide, sodium azide, and potassium azide. In some embodiments, the alkali azide salt is lithium azide. In some embodiments, the alkali azide salt is sodium azide. In some embodiments, the alkali azide salt is potassium azide. In some embodiments, the reaction of the compound of Formula (IIb) with the alkali azide salt is carried out in a solution comprising an aprotic solvent, a protic solvent, or a mixture thereof. In some embodiments, the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethyl sulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols. In some embodiments, the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N-methylpyrrolidine, dimethyl sulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane. In some embodiments, the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N,N-dimethylformamide, and 1,4-dioxane. In some embodiments, the aprotic solvent is acetonitrile. In some embodiments, the aprotic solvent is tetrahydrofuran. In some embodiments, the aprotic solvent is 2-methyltetrahydrofuran. In some embodiments, the aprotic solvent is N,N-dimethylformamide. In some embodiments, the aprotic solvent is 1,4-dioxane. In some embodiments, the reaction of the compound of Formula (IIb) with an alkali azide salt is carried out in a solution comprising a mixture of an aprotic solvent and a protic solvent.In some embodiments, the protic solvent is selected from water and an alcohol. In some embodiments, the protic solvent is water. In some embodiments, the protic solvent is an alcohol. In some embodiments, the alcohol is selected from methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, n-pentanol, and isopentanol. In some embodiments, the alcohol is selected from methanol, ethanol, n-propanol, and isopropanol. In some embodiments, the solution comprises a mixture of water and 1,4-dioxane. In some embodiments, the solution comprises a mixture of water and acetonitrile.

[0105] Compound of formula (VI) Further disclosed herein is a compound of formula (VI) [ka] or a salt thereof, comprising the steps of: [ka] with an acid. In some embodiments, the compound of formula (VI) is isolated as its salt. In some embodiments, the compound of formula (VI) is converted to its salt using methods known to those of skill in the art. In some embodiments, the reaction of the compound of formula (III) with the acid is carried out in a solution containing an aprotic solvent, a protic solvent, or a mixture thereof. Aprotic solvents that can be used to carry out the reaction include, but are not limited to, acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols. In some embodiments, the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane. In other cases, the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N,N-dimethylformamide, and 1,4-dioxane. In some embodiments, the aprotic solvent is acetonitrile. In some embodiments, the aprotic solvent is tetrahydrofuran. In some embodiments, the aprotic solvent is 2-methyltetrahydrofuran. In some embodiments, the aprotic solvent is N,N-dimethylformamide. In some embodiments, the aprotic solvent is 1,4-dioxane. In some cases, the reaction of the compound of formula (III) with the acid is carried out in a solution comprising a mixture of a protic solvent and an aprotic solvent, where the protic solvent comprises, for example, water. In some embodiments, the reaction of the compound of Formula (III) with the acid is carried out in a solution comprising a mixture of 1,4-dioxane and water.The reaction of the compound of formula (III) with the acid can be carried out using an acid including, but not limited to, phosphoric acid, hydrochloric acid, acetic acid, and trifluoroacetic acid. In some cases, the acid can be phosphoric acid. In other cases, the acid can be hydrochloric acid. In still other cases, the acid can be acetic acid. In further cases, the acid can be trifluoroacetic acid. In some embodiments, a base is added to the acid mixture containing the compound of formula (III). In some embodiments, the base is ammonium hydroxide, sodium hydroxide, or potassium hydroxide. In some embodiments, the base is ammonium hydroxide. In some embodiments, a base is added to the acid mixture containing the compound of formula (III) to adjust the pH of the solution to a range of about 4-10. In some embodiments, a base is added to the acid mixture containing the compound of formula (III) to adjust the pH of the solution to a range of about 7-9.5. In some embodiments, the pH of the solution is adjusted to a range of about 8-9.5. In some embodiments, a base is added to the acid mixture containing the compound of formula (III) to adjust the pH of the solution to a range of about 7-9. In some embodiments, the pH of the solution is adjusted to a range of about 7 to 8. In some embodiments, the pH of the solution is adjusted to a range of about 8 to 9. In some embodiments, the pH of the solution is adjusted to about 4. In some embodiments, the pH of the solution is adjusted to about 5. In some embodiments, the pH of the solution is adjusted to about 6. In some embodiments, the pH of the solution is adjusted to about 7. In some embodiments, the pH of the solution is adjusted to about 8. In some embodiments, the pH of the solution is adjusted to about 9. In some embodiments, the pH of the solution is adjusted to about 10. The reaction can be carried out at a temperature in the range of about 0° C. to about 100° C., or about 25° C. to about 75° C., or about 25° C. to about 50° C., or at about 40° C. In some embodiments, the reaction is carried out at a temperature range of about 0° C. to about 50° C., such as about 10° C. to about 45° C.

[0106] An example of reacting a compound of formula (III) with an acid to obtain a compound of formula (VI) is shown below, where the compound of formula (III) is reacted with hydrochloric acid in a mixture of acetonitrile and water at a temperature of 40° C. to obtain a compound of formula (VI). The compound of formula (VI) can be isolated as a salt, for example the hydrochloride salt, or it can be isolated as a zwitterionic form of the compound by neutralization of the reaction mixture after reaction of the compound of formula (III) with an acid as shown in Scheme 10.

[0107] [ka]

[0108] Compounds of formula (VIa) and (VIb) may be prepared as described above for compounds of formula (VI), where a compound of formula (IIIa) or formula (IIIb) is reacted with an acid as described above and as shown in Schemes 11 and 12 below.

[0109] [ka]

[0110] Further disclosed herein is a compound of formula (VIa) [ka] or a salt thereof, comprising the steps of: [ka] with an acid. In some embodiments, the reaction of the compound of formula (IIIa) with an acid is carried out in a solution comprising an aprotic solvent, a protic solvent, or a mixture thereof. In some embodiments, the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols. In some embodiments, the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane. In some embodiments, the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N,N-dimethylformamide, and 1,4-dioxane. In some embodiments, the aprotic solvent is acetonitrile. In some embodiments, the aprotic solvent is tetrahydrofuran. In some embodiments, the aprotic solvent is 2-methyltetrahydrofuran. In some embodiments, the aprotic solvent is N,N-dimethylformamide. In some embodiments, the aprotic solvent is 1,4-dioxane. In some embodiments, the reaction of the compound of Formula (IIIa) with an acid is carried out in a solution comprising a mixture of a protic solvent and an aprotic solvent, where the protic solvent can be water. In some embodiments, the reaction of the compound of Formula (IIIa) with an acid is carried out in a solution comprising a mixture of 1,4-dioxane and water. In some embodiments, the acid is selected from phosphoric acid, hydrochloric acid, acetic acid, and trifluoroacetic acid. In some embodiments, the acid is phosphoric acid. In some embodiments, the acid is hydrochloric acid. In some embodiments, the acid is acetic acid.In some embodiments, the acid is trifluoroacetic acid. In some embodiments, a base is added to the acid mixture comprising Formula (IIIa). In some embodiments, the base is ammonium hydroxide, sodium hydroxide, or potassium hydroxide. In some embodiments, the base is ammonium hydroxide. In some embodiments, a base is added to the acid mixture comprising Formula (IIIa) to adjust the pH of the solution to a range of about 4-10. In some embodiments, a base is added to the acid mixture comprising Formula (IIIa) to adjust the pH of the solution to a range of about 7-9. In some embodiments, the pH of the solution is adjusted to a range of about 8-9. In some embodiments, the pH of the solution is adjusted to about 4. In some embodiments, the pH of the solution is adjusted to about 5. In some embodiments, the pH of the solution is adjusted to about 6. In some embodiments, the pH of the solution is adjusted to about 7. In some embodiments, the pH of the solution is adjusted to about 8. In some embodiments, the pH of the solution is adjusted to about 8. In some embodiments, the pH of the solution is adjusted to about 9. In some embodiments, the pH of the solution is adjusted to about 10.

[0111] Further disclosed herein is a compound of formula (VIb): [ka] or a salt thereof, comprising the steps of: [ka] with an acid. In some embodiments, the reaction of the compound of formula (IIIb) with an acid is carried out in a solution comprising an aprotic solvent, a protic solvent, or a mixture thereof. In some embodiments, the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols. In some embodiments, the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane. In some embodiments, the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N,N-dimethylformamide, and 1,4-dioxane. In some embodiments, the aprotic solvent is acetonitrile. In some embodiments, the aprotic solvent is tetrahydrofuran. In some embodiments, the aprotic solvent is 2-methyltetrahydrofuran. In some embodiments, the aprotic solvent is N,N-dimethylformamide. In some embodiments, the aprotic solvent is 1,4-dioxane. In some embodiments, the reaction of the compound of Formula (IIIb) with an acid is carried out in a solution comprising a mixture of a protic solvent and an aprotic solvent, where the protic solvent can be water. In some embodiments, the reaction of the compound of Formula (IIIb) with an acid is carried out in a solution comprising a mixture of 1,4-dioxane and water. In some embodiments, the acid is selected from phosphoric acid, hydrochloric acid, acetic acid, and trifluoroacetic acid. In some embodiments, the acid is phosphoric acid. In some embodiments, the acid is hydrochloric acid. In some embodiments, the acid is acetic acid.In some embodiments, the acid is trifluoroacetic acid. In some embodiments, a base is added to the acid mixture comprising Formula (IIIb). In some embodiments, the base is ammonium hydroxide, sodium hydroxide, or potassium hydroxide. In some embodiments, the base is ammonium hydroxide. In some embodiments, a base is added to the acid mixture comprising Formula (IIIb) to adjust the pH of the solution to a range of about 4-10. In some embodiments, a base is added to the acid mixture comprising Formula (IIIb) to adjust the pH of the solution to a range of about 7-9. In some embodiments, the pH of the solution is adjusted to a range of about 8-9. In some embodiments, the pH of the solution is adjusted to about 4. In some embodiments, the pH of the solution is adjusted to about 5. In some embodiments, the pH of the solution is adjusted to about 6. In some embodiments, the pH of the solution is adjusted to about 7. In some embodiments, the pH of the solution is adjusted to about 8. In some embodiments, the pH of the solution is adjusted to about 8. In some embodiments, the pH of the solution is adjusted to about 9. In some embodiments, the pH of the solution is adjusted to about 10.

[0112] In one embodiment, provided herein is a method of making a compound of formula (VI), or a salt thereof, as outlined in Scheme 13.

[0113] [ka] (In the formula, R 1 is chloro, bromo, or iodo).

[0114] R 1 In some embodiments where is chloro, compounds of formula (VI) are prepared as outlined in Scheme 14.

[0115] [ka]

[0116] In some variations, compounds of formula (VIa) and (VIb), or salts thereof, are prepared as outlined in Scheme 15 and Scheme 16.

[0117] [ka]

[0118] Compound of formula (VII) Further disclosed herein is a compound of formula (VII) [ka] (In the formula: R 3 is selected from chloro, bromo and iodo; R 4 -OR 6 , -CF3, -CH2C6~C 12 aryl, and C1-C6 alkyl; R 5 is -CH2C6~C 12 aryl or C1-C6 alkyl; R 6 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 aryl) It is a compound of the formula:

[0119] In some embodiments of the compound of Formula (VII), R 4 -OR 6 and R 5 is C1-C6 alkyl. In some embodiments, R 6 is C1-C6 alkyl. In some embodiments, C1-C6 alkyl is tert-butyl. In some embodiments, R 5 is tert-butyl.

[0120] In some embodiments of the compound of Formula (VII), R 3 is chloro. In some embodiments, R6 is C1-C6 alkyl. In some embodiments, C1-C6 alkyl is tert-butyl. In some embodiments, R 5 is tert-butyl. In some embodiments, R 4 -OR 6 and R 5 is C1-C6 alkyl.

[0121] In some embodiments of the compound of Formula (VII), R 3 is bromo. In some embodiments, R 6 is C1-C6 alkyl. In some embodiments, C1-C6 alkyl is tert-butyl. In some embodiments, R 5 is tert-butyl. In some embodiments, R 4 -OR 6 and R 5 is C1-C6 alkyl.

[0122] In some embodiments of the compound of Formula (VII), R 3 is iodo. In some embodiments, R 6 is C1-C6 alkyl. In some embodiments, C1-C6 alkyl is tert-butyl. In some embodiments, R 5 is tert-butyl. In some embodiments, R 4 -OR 6 and R 5 is C1-C6 alkyl.

[0123] Further disclosed herein is a compound of formula (VIIa) [ka] (In the formula: R 3 is selected from chloro, bromo and iodo; R 4 -OR 6 , -CF3, -CH2C6~C 12aryl, and C1-C6 alkyl; R 5 is -CH2C6~C 12 aryl or C1-C6 alkyl; R 6 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 aryl) It is a compound of the formula:

[0124] In some embodiments of the compound of Formula (VIIa), R 6 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 In some embodiments, R 4 -OR 6 and R 5 is C1-C6 alkyl. In some embodiments, R 6 is C1-C6 alkyl. In some embodiments, C1-C6 alkyl is tert-butyl. In some embodiments, R 5 is tert-butyl.

[0125] In some embodiments of the compound of Formula (VIIa), R 3 is chloro. In some embodiments, R 6 is C1-C6 alkyl. In some embodiments, C1-C6 alkyl is tert-butyl. In some embodiments, R 5 is tert-butyl. In some embodiments, R 4 -OR 6 and R 5 is C1-C6 alkyl.

[0126] In some embodiments of the compound of Formula (VIIa), R 3 is bromo. In some embodiments, R 6is C1-C6 alkyl. In some embodiments, C1-C6 alkyl is tert-butyl. In some embodiments, R 5 is tert-butyl. In some embodiments, R 4 -OR 6 and R 5 is C1-C6 alkyl.

[0127] In some embodiments of the compound of Formula (VIIa), R 3 is iodo. In some embodiments, R 6 is C1-C6 alkyl. In some embodiments, C1-C6 alkyl is tert-butyl. In some embodiments, R 5 is tert-butyl. In some embodiments, R 4 -OR 6 and R 5 is C1-C6 alkyl.

[0128] Further disclosed herein is a compound of formula (VIIb) [ka] (In the formula: R 3 is selected from chloro, bromo and iodo; R 4 -OR 6 , -CF3, -CH2C6~C 12 selected from aryl and C1-C6 alkyl; R 5 is -CH2C6~C 12 aryl or C1-C6 alkyl; R 6 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 aryl). In some embodiments, R 6 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12aryl.

[0129] In some embodiments of the compound of Formula (VIIb), R 4 -OR 6 and R 5 is C1-C6 alkyl. In some embodiments, R 6 is C1-C6 alkyl. In some embodiments, C1-C6 alkyl is tert-butyl. In some embodiments, R 5 is tert-butyl.

[0130] In some embodiments of the compound of Formula (VIIb), R 3 is chloro. In some embodiments, R 6 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 In some embodiments, R 4 -OR 6 and R 5 is C1-C6 alkyl. In some embodiments, R 6 is C1-C6 alkyl. In some embodiments, C1-C6 alkyl is tert-butyl. In some embodiments, R 5 is tert-butyl.

[0131] In some embodiments of the compound of Formula (VIIb), R 3 is bromo. In some embodiments, R 6 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 In some embodiments, R 4 -OR 6 and R 5 is C1-C6 alkyl. In some embodiments, R 6 is C1-C6 alkyl. In some embodiments, C1-C6 alkyl is tert-butyl. In some embodiments, R5 is tert-butyl.

[0132] In some embodiments of the compound of Formula (VIIb), R 3 is iodo. In some embodiments, R 6 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 In some embodiments, R 4 -OR 6 and R 5 is C1-C6 alkyl. In some embodiments, R 6 is C1-C6 alkyl. In some embodiments, C1-C6 alkyl is tert-butyl. In some embodiments, R 5 is tert-butyl.

[0133] Compound of formula (VIII) Further disclosed herein is a compound of formula (VIII) [ka] (In the formula: R 7 -OR 9 , -CF3, -CH2C6~C 12 aryl, and C1-C6 alkyl; R 8 is -CH2C6~C 12 aryl or C1-C6 alkyl; R 9 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 aryl) It is a compound of the formula:

[0134] In some embodiments of the compound of Formula (VIII), R 7 -OR 9 and R 8 is C1-C6 alkyl. In some embodiments, R 9is C1-C6 alkyl. In some embodiments, C1-C6 alkyl is tert-butyl. In some embodiments, R 8 is tert-butyl.

[0135] Further disclosed herein is a compound of formula (VIIIa) [ka] (In the formula: R 7 -OR 9 , -CF3, -CH2C6~C 12 aryl, and C1-C6 alkyl; R 8 is -CH2C6~C 12 aryl or C1-C6 alkyl; R 9 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 aryl). In some embodiments, R 7 -OR 9 and R 8 is C1-C6 alkyl.

[0136] In some embodiments of the compound of Formula (VIIIa), R 9 is C1-C6 alkyl. In some embodiments, C1-C6 alkyl is tert-butyl. In some embodiments, R 8 is tert-butyl.

[0137] Further disclosed herein is a compound of formula (VIIIb) [ka] (In the formula: R 7 -OR 9 , -CF3, -CH2C6~C 12 aryl, and C1-C6 alkyl; R 8is -CH2C6~C 12 aryl or C1-C6 alkyl; R 9 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 aryl) It is a compound of the formula:

[0138] In some embodiments of the compound of Formula (VIIIb), R 7 -OR 9 and R 8 is C1-C6 alkyl. In some embodiments, R 9 is C1-C6 alkyl. In some embodiments, C1-C6 alkyl is tert-butyl. In some embodiments, R 8 is tert-butyl.

[0139] All compounds of formula (I), (II), (III), (IV), (V), (VI), (VII), or (VIII), or any modification thereof as described herein that exists in free base or acid form, can be converted to their salts by treatment with an appropriate inorganic or organic base or acid by methods known to those skilled in the art. Salts of the compounds of the present disclosure can be converted to their free base or acid form by standard techniques.

[0140] Exemplary embodiments The present disclosure is further described by the following embodiments, each of which may be combined with any of the other embodiments where appropriate and practical.

[0141] Embodiment P1. Formula (I) [ka] (In the formula, R 1 is selected from chloro, bromo and iodo Compound.

[0142] Embodiment P2.R 1 The compound according to embodiment P1, wherein is chloro.

[0143] Embodiment P3.R 1 A compound according to embodiment P1, wherein:

[0144] Embodiment P4.R 1 The compound according to embodiment P1, wherein:

[0145] Embodiment P5. Formula (II) [ka] (In the formula, R 1 is selected from chloro, bromo, and iodo. Compound.

[0146] Embodiment P6.R 1 The compound according to embodiment P5, wherein:

[0147] Embodiment P7.R 1 The compound according to embodiment P5, wherein:

[0148] Embodiment P8.R 1 The compound according to embodiment P5, wherein:

[0149] Embodiment P9. Formula (IIa) [ka] (In the formula, R 1 is selected from chloro, bromo, and iodo. Compound.

[0150] Embodiment P10.R 1 The compound according to embodiment P9, wherein is chloro.

[0151] Embodiment P11.R 1 The compound according to embodiment P9, wherein:

[0152] Embodiment P12.R 1 The compound according to embodiment P9, wherein:

[0153] Embodiment P13. Formula (IIb) [ka] (In the formula, R 1 is selected from chloro, bromo, and iodo. Compound.

[0154] Embodiment P14.R 1 The compound according to embodiment P13, wherein is chloro.

[0155] Embodiment P15.R 1 The compound according to embodiment P13, wherein is bromo.

[0156] Embodiment P16.R 1 The compound according to embodiment P13, wherein is iodo.

[0157] Embodiment P17. Formula (III) [ka] Compound.

[0158] Embodiment P18. Formula (IIIa) [ka] Compound.

[0159] Embodiment P19. Formula (IIIb) [ka] Compound.

[0160] Embodiment P20. Formula (I) [ka] A method for preparing a compound of formula (I), comprising the steps of: [ka] with N-hydroxysuccinimide, wherein in each of the compounds of formula (I) and (IV), R 1 are the same and are selected from chloro, bromo and iodo.

[0161] Embodiment P21.R 1 The method of embodiment P20, wherein is chloro.

[0162] Embodiment P22.R 1 The method of embodiment P20, wherein R is bromo.

[0163] Embodiment P23.R 1 The method of embodiment P20, wherein is iodine.

[0164] Embodiment P24. The method of any one of Embodiments P20-P23, wherein the reaction of the compound of Formula (IV) with N-hydroxysuccinimide is carried out in a solution comprising an aprotic solvent.

[0165] Embodiment P25. The method of embodiment P24, wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols.

[0166] Embodiment P26. The method of embodiment P25 wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane.

[0167] Embodiment P27. The method of embodiment P26 wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, and N,N-dimethylformamide.

[0168] Embodiment P28. The method of embodiment P27 wherein the aprotic solvent is acetonitrile.

[0169] Embodiment P29. The method of embodiment P27 wherein the aprotic solvent is acetone.

[0170] Embodiment P30. The method of embodiment P27 wherein the aprotic solvent is methyl ethyl ketone.

[0171] Embodiment P31. The method of embodiment P27 wherein the aprotic solvent is dichloromethane.

[0172] Embodiment P32. The method of embodiment P27 wherein the aprotic solvent is chloroform.

[0173] Embodiment P33. The method of embodiment P27 wherein the aprotic solvent is tetrahydrofuran.

[0174] Embodiment P34. The method of embodiment P27 wherein the aprotic solvent is N,N-dimethylformamide.

[0175] Embodiment P35. The method of any one of Embodiments P24-P34 wherein the solution further comprises a base.

[0176] Embodiment P36. The method of embodiment P35, wherein the base is selected from an organic base and an inorganic base.

[0177] Embodiment P37. The method of embodiment P36 wherein the organic base is selected from heterocyclic bases and trialkylamines, or mixtures thereof.

[0178] Embodiment P38. The method of embodiment P36 wherein the heterocyclic base is an aromatic heterocyclic base or a non-aromatic heterocyclic base, or a mixture of an aromatic heterocyclic base and a non-aromatic heterocyclic base.

[0179] Embodiment P39. The method of embodiment P38 wherein the heterocyclic base is an aromatic heterocyclic base.

[0180] Embodiment P40. The method of embodiment P39 wherein the aromatic heterocyclic base is selected from pyridine, 1-alkylpyrrole, and 1-alkylimidazole, or a mixture thereof.

[0181] Embodiment P41. The method of embodiment P40 wherein the aromatic heterocyclic base is selected from pyridine, 1-methylpyrrole, and 1-methylimidazole, or a mixture thereof.

[0182] Embodiment P42. The method of embodiment P41 wherein the aromatic heterocyclic base is pyridine.

[0183] Embodiment P43. The method of embodiment P41 wherein the aromatic heterocyclic base is 1-methylpyrrole.

[0184] Embodiment P44. The method of embodiment P41 wherein the aromatic heterocyclic base is 1-methylimidazole.

[0185] Embodiment P45. The method of embodiment P38 wherein the heterocyclic base is a non-aromatic heterocyclic base.

[0186] Embodiment P46. The method of embodiment P38 wherein the non-aromatic heterocyclic base is selected from N-alkylpyrrolidines, N-alkylpiperidines, N-alkylmorpholines, and 1,4-dialkylpiperazines, or mixtures thereof.

[0187] Embodiment P47. The method of embodiment P46 wherein the non-aromatic heterocyclic base is an N-alkylpyrrolidine.

[0188] Embodiment P48. The method of embodiment P46 wherein the non-aromatic heterocyclic base is an N-alkylpiperidine.

[0189] Embodiment P49. The method of embodiment P46 wherein the non-aromatic heterocyclic base is an N-alkylmorpholine.

[0190] Embodiment P50. The method of embodiment P46 wherein the non-aromatic heterocyclic base is a 1,4-dialkylpiperazine.

[0191] Embodiment P51. The method of embodiment P46 wherein the non-aromatic heterocyclic base is selected from N-methylpyrrolidine, N-methylpiperidine, and N-methylmorpholine.

[0192] Embodiment P52. The method of embodiment P51 wherein the non-aromatic heterocyclic base is N-methylpyrrolidine.

[0193] Embodiment P53. The method of embodiment P51 wherein the non-aromatic heterocyclic base is N-methylpiperidine.

[0194] Embodiment P54. The method of embodiment P51 wherein the non-aromatic heterocyclic base is N-methylmorpholine.

[0195] Embodiment P55. The method of embodiment P37 wherein the organic base is a trialkylamine.

[0196] Embodiment P56. The method of embodiment P55 wherein the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, tri-n-butylamine, tripentylamine, trihexylamine, and diisopropylethylamine.

[0197] Embodiment P57. The method of embodiment P56 wherein the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, and diisopropylethylamine.

[0198] Embodiment P58. The method of embodiment P57 wherein the trialkylamine is selected from triethylamine, tri-n-propylamine, and diisopropylethylamine.

[0199] Embodiment P59. The method of embodiment P58, wherein the trialkylamine is triethylamine or diisopropylethylamine.

[0200] Embodiment P60. The method of embodiment P58 wherein the trialkylamine is triethylamine.

[0201] Embodiment P61. The method of embodiment P58 wherein the trialkylamine is diisopropylethylamine.

[0202] Embodiment P62.R 1 The method of embodiment P24, wherein is chloro and the aprotic solvent is acetonitrile.

[0203] Embodiment P63. The method of embodiment P62 wherein the solution further comprises a base.

[0204] Embodiment P64. The method of embodiment P63 wherein the base is selected from trialkylamines.

[0205] Embodiment P65. The method of embodiment P64 wherein the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, tri-n-butylamine, tripentylamine, trihexylamine, and diisopropylethylamine.

[0206] Embodiment P66. The method of embodiment P65 wherein the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, and diisopropylethylamine.

[0207] Embodiment P67. The method of embodiment P66 wherein the trialkylamine is selected from triethylamine, tri-n-propylamine, and diisopropylethylamine.

[0208] Embodiment P68. The method of embodiment P67 wherein the trialkylamine is triethylamine or diisopropylethylamine.

[0209] Embodiment P69. The method of embodiment P68 wherein the trialkylamine is triethylamine.

[0210] Embodiment P70. The method of embodiment P68 wherein the trialkylamine is diisopropylethylamine.

[0211] Embodiment P71.R 1 The method of embodiment P24, wherein is bromo and the aprotic solvent is acetonitrile.

[0212] Embodiment P72. The method of embodiment P71 wherein the solution further comprises a base.

[0213] Embodiment P73. The method of embodiment P72 wherein the base is selected from trialkylamines.

[0214] Embodiment P74. The method of embodiment P73 wherein the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, tri-n-butylamine, tripentylamine, trihexylamine, and diisopropylethylamine.

[0215] Embodiment P75. The method of embodiment P74 wherein the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, and diisopropylethylamine.

[0216] Embodiment P76. The method of embodiment P75 wherein the trialkylamine is selected from triethylamine, tri-n-propylamine, and diisopropylethylamine.

[0217] Embodiment P77. The method of embodiment P76, wherein the trialkylamine is triethylamine or diisopropylethylamine.

[0218] Embodiment P78. The method of embodiment P77 wherein the trialkylamine is triethylamine.

[0219] Embodiment P79. The method of embodiment P77 wherein the trialkylamine is diisopropylethylamine.

[0220] Embodiment P80.R 1 The method of embodiment P24, wherein is iodine and the aprotic solvent is acetonitrile.

[0221] Embodiment P81. The method of embodiment P80 wherein the solution further comprises a base.

[0222] Embodiment P82. The method of embodiment P81 wherein the base is selected from trialkylamines.

[0223] Embodiment P83. The method of embodiment P82 wherein the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, tri-n-butylamine, tripentylamine, trihexylamine, and diisopropylethylamine.

[0224] Embodiment P84. The method of embodiment P83 wherein the trialkylamine is selected from trimethylamine, triethylamine, tri-n-propylamine, and diisopropylethylamine.

[0225] Embodiment P85. The method of embodiment P84 wherein the trialkylamine is selected from triethylamine, tri-n-propylamine, and diisopropylethylamine.

[0226] Embodiment P86. The method of embodiment P85 wherein the trialkylamine is triethylamine or diisopropylethylamine.

[0227] Embodiment P87. The method of embodiment P86 wherein the trialkylamine is triethylamine.

[0228] Embodiment P88. The method of embodiment P86 wherein the trialkylamine is diisopropylethylamine.

[0229] Embodiment P89. Formula (II) [ka] A method for preparing a compound of formula (I) to obtain a compound of formula (II) [ka] With a compound of formula (V) [ka] wherein R in each of the compounds of formula (I) and (II) is 1are the same and are selected from chloro, bromo and iodo.

[0230] Embodiment P90. The method of Embodiment P89, wherein the reaction of a compound of Formula (V) with a compound of Formula (I) is carried out in a solution comprising an aprotic solvent.

[0231] Embodiment P91. The method of embodiment P90, wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols.

[0232] Embodiment P92. The method of embodiment P91 wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane.

[0233] Embodiment P93. The method of embodiment P92 wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, and N,N-dimethylformamide.

[0234] Embodiment P94. The method of embodiment P93 wherein the aprotic solvent is acetonitrile.

[0235] Embodiment P95. The method of embodiment P93 wherein the aprotic solvent is acetone.

[0236] Embodiment P96. The method of embodiment P93 wherein the aprotic solvent is methyl ethyl ketone.

[0237] Embodiment P97. The method of embodiment P93 wherein the aprotic solvent is dichloromethane.

[0238] Embodiment P98. The method of embodiment P93 wherein the aprotic solvent is chloroform.

[0239] Embodiment P99. The method of embodiment P93 wherein the aprotic solvent is tetrahydrofuran.

[0240] Embodiment P100. The method of embodiment P93 wherein the aprotic solvent is N,N-dimethylformamide.

[0241] Embodiment P101. R in each of the compounds of formula (I) and (II) 1 The method of any one of embodiments P89 to P100, wherein is chloro.

[0242] Embodiment P102. R in each of the compounds of formula (I) and (II) 1 The method of any one of embodiments P89 to P100, wherein is bromo.

[0243] Embodiment P103. R in each of the compounds of formula (I) and (II) 1 The method of any one of embodiments P89 to P100, wherein is iodine.

[0244] Embodiment P104. Formula (IIa) [ka] A method for preparing a compound of formula (I) comprising the steps of: [ka] The compound of formula (Va) [ka] wherein R in each of the compounds of formula (I) and (IIa) is 1 are the same and are selected from chloro, bromo and iodo.

[0245] Embodiment P105. The method of embodiment P104, wherein the reaction of the compound of Formula (Va) with the compound of Formula (I) is carried out in a solution comprising an aprotic solvent.

[0246] Embodiment P106. The method of embodiment P105, wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols.

[0247] Embodiment P107. The method of embodiment P106, wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane.

[0248] Embodiment P108. The method of embodiment P107, wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, and N,N-dimethylformamide.

[0249] Embodiment P109. The method of embodiment P108, wherein the aprotic solvent is acetonitrile.

[0250] Embodiment P110. The method of embodiment P108, wherein the aprotic solvent is acetone.

[0251] Embodiment P111. The method of embodiment P108 wherein the aprotic solvent is methyl ethyl ketone.

[0252] Embodiment P112. The method of embodiment P108 wherein the aprotic solvent is dichloromethane.

[0253] Embodiment P113. The method of embodiment P108, wherein the aprotic solvent is chloroform.

[0254] Embodiment P114. The method of embodiment P108 wherein the aprotic solvent is tetrahydrofuran.

[0255] Embodiment P115. The method of embodiment P108, wherein the aprotic solvent is N,N-dimethylformamide.

[0256] Embodiment P116. R in each of the compounds of formula (I) and (IIa) 1 The method of any one of embodiments P104 to P115, wherein is chloro.

[0257] Embodiment P117. R in each of the compounds of formula (I) and (IIa) 1 The method according to any one of embodiments P104 to P115, wherein is bromo.

[0258] Embodiment P118. R in each of the compounds of formula (I) and (IIa) 1 The method of any one of embodiments P104 to P115, wherein is iodine.

[0259] Embodiment P119. Formula (IIb) [ka] A method for preparing a compound of formula (I) comprising the steps of: [ka] With a compound of formula (Vb) [ka] wherein R in each of the compounds of formula (I) and (IIb) is 1 are the same and are selected from chloro, bromo and iodo.

[0260] Embodiment P120. The method of embodiment P119, wherein the reaction of a compound of Formula (Vb) with a compound of Formula (I) is carried out in a solution comprising an aprotic solvent.

[0261] Embodiment P121. The method of embodiment P120, wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols.

[0262] Embodiment P122. The method of embodiment P121, wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane.

[0263] Embodiment P123. The method of embodiment P122, wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, and N,N-dimethylformamide.

[0264] Embodiment P124. The method of embodiment P123 wherein the aprotic solvent is acetonitrile.

[0265] Embodiment P125. The method of embodiment P123 wherein the aprotic solvent is acetone.

[0266] Embodiment P126. The method of embodiment P123 wherein the aprotic solvent is methyl ethyl ketone.

[0267] Embodiment P127. The method of embodiment P123 wherein the aprotic solvent is dichloromethane.

[0268] Embodiment P128. The method of embodiment P123, wherein the aprotic solvent is chloroform.

[0269] Embodiment P129. The method of embodiment P123 wherein the aprotic solvent is tetrahydrofuran.

[0270] Embodiment P130. The method of embodiment P123 wherein the aprotic solvent is N,N-dimethylformamide.

[0271] Embodiment P131. R in each of the compounds of formula (I) and (IIb) 1 The method according to any one of embodiments P119 to P130, wherein is chloro.

[0272] Embodiment P132. R in each of the compounds of formula (I) and (IIb) 1 The method according to any one of embodiments P119 to P130, wherein is bromo.

[0273] Embodiment P133. R in each of the compounds of formula (I) and (IIb) 1 The method according to any one of embodiments P119 to P130, wherein is iodine.

[0274] Embodiment P134. Formula (III) [ka] The method for preparing a compound of formula (III) comprises the steps of: [ka] (In the formula, R 1 is selected from chloro, bromo, and iodo) with an alkali azide salt.

[0275] Embodiment P135. The method of embodiment P134, wherein the alkali azide salt is selected from lithium azide, sodium azide, and potassium azide.

[0276] Embodiment P136. The method of embodiment P135, wherein the alkali azide salt is lithium azide.

[0277] Embodiment P137. The method of embodiment P135, wherein the alkali azide salt is sodium azide.

[0278] Embodiment P138. The method of embodiment P135, wherein the alkali azide salt is potassium azide.

[0279] Embodiment P139. The method of any one of Embodiments P134 to P138, wherein the reaction of the compound of Formula (II) with an alkali azide salt is carried out in a solution comprising an aprotic solvent, a protic solvent, or a mixture thereof.

[0280] Embodiment P140. The method of embodiment P139, wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols.

[0281] Embodiment P141. The method of embodiment P140, wherein the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane.

[0282] Embodiment P142. The method of embodiment P141, wherein the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N,N-dimethylformamide, and 1,4-dioxane.

[0283] Embodiment P143. The method of embodiment P142 wherein the aprotic solvent is acetonitrile.

[0284] Embodiment P144. The method of embodiment P142 wherein the aprotic solvent is tetrahydrofuran.

[0285] Embodiment P145. The method of embodiment P142 wherein the aprotic solvent is N,N-dimethylformamide.

[0286] Embodiment P146. The method of embodiment P142, wherein the aprotic solvent is 1,4-dioxane.

[0287] Embodiment P147. The method of embodiment P139, wherein the reaction of the compound of formula (II) with an alkali azide salt is carried out in a solution comprising a mixture of an aprotic solvent and a protic solvent.

[0288] Embodiment P148. The method of embodiment P147, wherein the solution further comprises a protic solvent.

[0289] Embodiment P149. The method of embodiment P148, wherein the protic solvent is selected from water and an alcohol.

[0290] Embodiment P150. The method of embodiment P149 wherein the protic solvent is water.

[0291] Embodiment P151. The method of embodiment P149 wherein the protic solvent is an alcohol.

[0292] Embodiment P152. The method of embodiment P151, wherein the alcohol is selected from methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, n-pentanol, and isopentanol.

[0293] Embodiment P153. The method of embodiment P152, wherein the alcohol is selected from methanol, ethanol, n-propanol, and isopropanol.

[0294] Embodiment P154. The method of embodiment P139 wherein the solution comprises a mixture of water and 1,4-dioxane.

[0295] Embodiment P155. Formula (IIIa) [ka] A method for preparing a compound of formula (IIa) comprising the steps of: [ka] (In the formula, R 1 is selected from chloro, bromo, and iodo) with an alkali azide salt.

[0296] Embodiment P156. The method of embodiment P155, wherein the alkali azide salt is selected from lithium azide, sodium azide, and potassium azide.

[0297] Embodiment P157. The method of embodiment P156, wherein the alkali azide salt is lithium azide.

[0298] Embodiment P158. The method of embodiment P156, wherein the alkali azide salt is sodium azide.

[0299] Embodiment P159. The method of embodiment P156, wherein the alkali azide salt is potassium azide.

[0300] Embodiment P160. The method of any one of Embodiments P155 to P159, wherein the reaction of the compound of Formula (IIa) with an alkali azide salt is carried out in a solution comprising an aprotic solvent, a protic solvent, or a mixture thereof.

[0301] Embodiment P161. The method of embodiment P160, wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols.

[0302] Embodiment P162. The method of embodiment P161, wherein the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane.

[0303] Embodiment P163. The method of embodiment P162, wherein the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N,N-dimethylformamide, and 1,4-dioxane.

[0304] Embodiment P164. The method of embodiment P163, wherein the aprotic solvent is acetonitrile.

[0305] Embodiment P165. The method of embodiment P163 wherein the aprotic solvent is tetrahydrofuran.

[0306] Embodiment P166. The method of embodiment P163, wherein the aprotic solvent is N,N-dimethylformamide.

[0307] Embodiment P167. The method of embodiment P163, wherein the aprotic solvent is 1,4-dioxane.

[0308] Embodiment P168. The method of embodiment P160, wherein the reaction of the compound of Formula (IIa) with an alkali azide salt is carried out in a solution comprising a mixture of an aprotic solvent and a protic solvent.

[0309] Embodiment P169. The method of any one of Embodiments P161 to P168, wherein the solution further comprises a protic solvent.

[0310] Embodiment P170. The method of embodiment P169, wherein the protic solvent is selected from water and an alcohol.

[0311] Embodiment P171. The method of embodiment P170, wherein the protic solvent is water.

[0312] Embodiment P172. The method of embodiment P170 wherein the protic solvent is an alcohol.

[0313] Embodiment P173. The method of embodiment P172, wherein the alcohol is selected from methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, n-pentanol, and isopentanol.

[0314] Embodiment P174. The method of embodiment P173, wherein the alcohol is selected from methanol, ethanol, n-propanol, and isopropanol.

[0315] Embodiment P175. The method of embodiment P160 wherein the solution comprises a mixture of water and 1,4-dioxane.

[0316] Embodiment P176. Formula (IIIb) [ka] A method for preparing a compound of formula (IIb) to obtain a compound of formula (IIIb) [ka] (In the formula, R 1 is selected from chloro, bromo, and iodo) with an alkali azide salt.

[0317] Embodiment P177. The method of embodiment P176, wherein the alkali azide salt is selected from lithium azide, sodium azide, and potassium azide.

[0318] Embodiment P178. The method of embodiment P177, wherein the alkali azide salt is lithium azide.

[0319] Embodiment P179. The method of embodiment P177, wherein the alkali azide salt is sodium azide.

[0320] Embodiment P180. The method of embodiment P177, wherein the alkali azide salt is potassium azide.

[0321] Embodiment P181. The method of any one of Embodiments P176 to P180, wherein the reaction of the compound of Formula (IIb) with an alkali azide salt is carried out in a solution comprising an aprotic solvent, a protic solvent, or a mixture thereof.

[0322] Embodiment P182. The method of embodiment P181, wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400 and polyethylene glycols.

[0323] Embodiment P183. The method of embodiment P182, wherein the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane.

[0324] Embodiment P184. The method of embodiment P183, wherein the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N,N-dimethylformamide, and 1,4-dioxane.

[0325] Embodiment P185. The method of embodiment P184, wherein the aprotic solvent is acetonitrile.

[0326] Embodiment P186. The method of embodiment P184 wherein the aprotic solvent is tetrahydrofuran.

[0327] Embodiment P187. The method of embodiment P184, wherein the aprotic solvent is N,N-dimethylformamide.

[0328] Embodiment P188. The method of embodiment P184, wherein the aprotic solvent is 1,4-dioxane.

[0329] Embodiment P189. The method of Embodiment P181, wherein the reaction of the compound of Formula (IIb) with an alkali azide salt is carried out in a solution comprising a mixture of an aprotic solvent and a protic solvent.

[0330] Embodiment P190. The method of any one of Embodiments P182 to P188, wherein the solution further comprises a protic solvent.

[0331] Embodiment P191. The method of embodiment P190, wherein the protic solvent is selected from water and an alcohol.

[0332] Embodiment P192. The method of embodiment P191 wherein the protic solvent is water.

[0333] Embodiment P193. The method of embodiment P191 wherein the protic solvent is an alcohol.

[0334] Embodiment P194. The method of embodiment P193, wherein the alcohol is selected from methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, n-pentanol, and isopentanol.

[0335] Embodiment P195. The method of embodiment P194, wherein the alcohol is selected from methanol, ethanol, n-propanol, and isopropanol.

[0336] Embodiment P196. The method of embodiment P195 wherein the solution comprises a mixture of water and 1,4-dioxane.

[0337] Embodiment P197. Formula (VI) [ka] or a salt thereof, comprising the steps of: [ka] with an acid.

[0338] Embodiment P198. The method of embodiment P197, wherein the reaction of the compound of formula (III) with the acid is carried out in a solution comprising an aprotic solvent, a protic solvent, or a mixture thereof.

[0339] Embodiment P199. The method of embodiment P198, wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400 and polyethylene glycols.

[0340] Embodiment P200. The method of embodiment P199, wherein the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane.

[0341] Embodiment P201. The method of embodiment P200, wherein the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N,N-dimethylformamide, and 1,4-dioxane.

[0342] Embodiment P202. The method of embodiment P201 wherein the aprotic solvent is acetonitrile.

[0343] Embodiment P203. The method of embodiment P201 wherein the aprotic solvent is tetrahydrofuran.

[0344] Embodiment P204. The method of embodiment P201 wherein the aprotic solvent is N,N-dimethylformamide.

[0345] Embodiment P205. The method of embodiment P201 wherein the aprotic solvent is 1,4-dioxane.

[0346] Embodiment P206. The method of embodiment P198, wherein the reaction of the compound of formula (III) with the acid is carried out in a solution comprising a mixture of a protic solvent and an aprotic solvent.

[0347] Embodiment P207. The method of any one of Embodiments P198 to P206, wherein the protic solvent is water.

[0348] Embodiment P208. The method of embodiment P198, wherein the reaction of a compound of formula (III) with an acid is carried out in a solution comprising a mixture of 1,4-dioxane and water.

[0349] Embodiment P209. The method of any one of Embodiments P197 to P208, wherein the acid is selected from phosphoric acid, hydrochloric acid, acetic acid, and trifluoroacetic acid.

[0350] Embodiment P210. The method of embodiment P209 wherein the acid is phosphoric acid.

[0351] Embodiment P211. The method of embodiment P209, wherein the acid is hydrochloric acid.

[0352] Embodiment P212. The method of embodiment P209 wherein the acid is acetic acid.

[0353] Embodiment P213. The method of embodiment P209 wherein the acid is trifluoroacetic acid.

[0354] Embodiment P214. Formula (VIa) [ka] or a salt thereof, comprising the steps of: [ka] with an acid.

[0355] Embodiment P215. The method of Embodiment P214, wherein the reaction of the compound of Formula (IIIa) with the acid is carried out in a solution comprising an aprotic solvent, a protic solvent, or a mixture thereof.

[0356] Embodiment P216. The method of embodiment P215, wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols.

[0357] Embodiment P217. The method of embodiment P216, wherein the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane.

[0358] Embodiment P218. The method of embodiment P217, wherein the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N,N-dimethylformamide, and 1,4-dioxane.

[0359] Embodiment P219. The method of embodiment P218 wherein the aprotic solvent is acetonitrile.

[0360] Embodiment P220. The method of embodiment P218 wherein the aprotic solvent is tetrahydrofuran.

[0361] Embodiment P221. The method of embodiment P218 wherein the aprotic solvent is N,N-dimethylformamide.

[0362] Embodiment P222. The method of embodiment P218 wherein the aprotic solvent is 1,4-dioxane.

[0363] Embodiment P223. The method of Embodiment P214, wherein the reaction of the compound of Formula (IIIa) with the acid is carried out in a solution comprising a mixture of a protic solvent and an aprotic solvent.

[0364] Embodiment P224. The method of any one of Embodiments P215 to P223 wherein the protic solvent is water.

[0365] Embodiment P225. The method of Embodiment P215, wherein the reaction of the compound of Formula (IIIa) with the acid is carried out in a solution comprising a mixture of 1,4-dioxane and water.

[0366] Embodiment P226. The method of any one of Embodiments P214 to P225, wherein the acid is selected from phosphoric acid, hydrochloric acid, acetic acid, and trifluoroacetic acid.

[0367] Embodiment P227. The method of embodiment P226, wherein the acid is phosphoric acid.

[0368] Embodiment P228. The method of embodiment P226, wherein the acid is hydrochloric acid.

[0369] Embodiment P229. The method of embodiment P226, wherein the acid is acetic acid.

[0370] Embodiment P230. The method of embodiment P226 wherein the acid is trifluoroacetic acid.

[0371] Embodiment P231. Formula (VIb) [ka] or a salt thereof, comprising the steps of: [ka] with an acid.

[0372] Embodiment P232. The method of Embodiment P231, wherein the reaction of the compound of Formula (IIIb) with the acid is carried out in a solution comprising an aprotic solvent, a protic solvent, or a mixture thereof.

[0373] Embodiment P233. The method of embodiment P232, wherein the aprotic solvent is selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400, and polyethylene glycols.

[0374] Embodiment P234. The method of embodiment P233, wherein the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, and 1,4-dioxane.

[0375] Embodiment P235. The method of embodiment P234 wherein the aprotic solvent is selected from acetonitrile, tetrahydrofuran, N,N-dimethylformamide, and 1,4-dioxane.

[0376] Embodiment P236. The method of embodiment P235 wherein the aprotic solvent is acetonitrile.

[0377] Embodiment P237. The method of embodiment P235 wherein the aprotic solvent is tetrahydrofuran.

[0378] Embodiment P238. The method of embodiment P235 wherein the aprotic solvent is N,N-dimethylformamide.

[0379] Embodiment P239. The method of embodiment P235 wherein the aprotic solvent is 1,4-dioxane.

[0380] Embodiment P240. The method of Embodiment P232, wherein the reaction of the compound of Formula (IIIb) with the acid is carried out in a solution comprising a mixture of a protic solvent and an aprotic solvent.

[0381] Embodiment P241. The method of any one of Embodiments P232 to P240 wherein the protic solvent is water.

[0382] Embodiment P242. The method of embodiment P232, wherein the reaction of the compound of Formula (IIIb) with the acid is carried out in a solution comprising a mixture of 1,4-dioxane and water.

[0383] Embodiment P243. The method of any one of Embodiments P231 to P242 wherein the acid is selected from phosphoric acid, hydrochloric acid, acetic acid, and trifluoroacetic acid.

[0384] Embodiment P244. The method of embodiment P243 wherein the acid is phosphoric acid.

[0385] Embodiment P245. The method of embodiment P243 wherein the acid is hydrochloric acid.

[0386] Embodiment P246. The method of embodiment P243 wherein the acid is acetic acid.

[0387] Embodiment P247. The method of embodiment P243 wherein the acid is trifluoroacetic acid.

[0388] Embodiment P248. Formula (VII) [ka] (In the formula: R 3 is selected from chloro, bromo and iodo; R 4 -OR 6 , -CF3, -CH2C6~C 12 aryl, and C1-C6 alkyl; R 5is -CH2C6~C 12 aryl or C1-C6 alkyl; R 6 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 aryl) Compound.

[0389] Embodiment P249.R 3 The compound according to embodiment P248, wherein is chloro.

[0390] Embodiment P250.R 3 The compound according to embodiment P248, wherein is bromo.

[0391] Embodiment P251.R 3 The compound according to embodiment P248, wherein is iodo.

[0392] Embodiment P252.R 4 -OR 6 and R 5 The compound according to embodiment P249, wherein is C1-C6 alkyl.

[0393] Embodiment P253.R 6 The compound according to embodiment P252, wherein is C1-C6 alkyl.

[0394] Embodiment P254. A compound according to Embodiment P253, wherein C1-C6 alkyl is tert-butyl.

[0395] Embodiment P255.R 5 The compound according to embodiment P254, wherein is tert-butyl.

[0396] Embodiment P256.R 4 -OR 6 and R 5 The compound according to embodiment P250, wherein is C1-C6 alkyl.

[0397] Embodiment P257.R 6The compound according to embodiment P256, wherein is C1-C6 alkyl.

[0398] Embodiment P258. A compound according to embodiment P257, wherein C1-C6 alkyl is tert-butyl.

[0399] Embodiment P259.R 5 The compound according to embodiment P258, wherein is tert-butyl.

[0400] Embodiment P260.R 4 -OR 6 and R 5 The compound according to embodiment P251, wherein is C1-C6 alkyl.

[0401] Embodiment P261.R 6 The compound according to embodiment P260, wherein is C1-C6 alkyl.

[0402] Embodiment P262. A compound according to Embodiment P261 wherein C1-C6 alkyl is tert-butyl.

[0403] Embodiment P263.R 5 The compound according to embodiment P262, wherein is tert-butyl.

[0404] Embodiment P264. Formula (VIIa) [ka] (In the formula: R 3 is selected from chloro, bromo and iodo; R 4 -OR 6 , -CF3, -CH2C6~C 12 aryl, and C1-C6 alkyl; R 5 is -CH2C6~C 12 aryl or C1-C6 alkyl; R 6 is C1-C6 alkyl, C6-C 12Aryl, and -CH2C6~C 12 aryl) Compound.

[0405] Embodiment P265.R 3 The compound according to embodiment P264, wherein is chloro.

[0406] Embodiment P266.R 3 The compound according to embodiment P264, wherein is bromo.

[0407] Embodiment P267.R 3 The compound according to embodiment P264, wherein is iodo.

[0408] Embodiment P268.R 4 -OR 6 and R 5 The compound according to embodiment P265, wherein is C1-C6 alkyl.

[0409] Embodiment P269.R 6 The compound according to embodiment P268, wherein is C1-C6 alkyl.

[0410] Embodiment P270. A compound according to Embodiment P269 wherein C1-C6 alkyl is tert-butyl.

[0411] Embodiment P271.R 5 The compound according to embodiment P270, wherein is tert-butyl.

[0412] Embodiment P272.R 4 -OR 6 and R 5 The compound according to embodiment P266, wherein is C1-C6 alkyl.

[0413] Embodiment P273.R 6 The compound according to embodiment P272, wherein is C1-C6 alkyl.

[0414] Embodiment P274. A compound according to Embodiment P273, wherein C1-C6 alkyl is tert-butyl.

[0415] Embodiment P275.R 5 The compound according to embodiment P274, wherein is tert-butyl.

[0416] Embodiment P276.R 4 -OR 6 and R 5 The compound according to embodiment P267, wherein is C1-C6 alkyl.

[0417] Embodiment P277.R 6 The compound according to embodiment P276, wherein is C1-C6 alkyl.

[0418] Embodiment P278. A compound according to embodiment P277, wherein C1-C6 alkyl is tert-butyl.

[0419] Embodiment P279.R 5 The compound according to embodiment P278, wherein is tert-butyl.

[0420] Embodiment P280. Formula (VIIb) [ka] (In the formula: R 3 is selected from chloro, bromo and iodo; R 4 -OR 6 , -CF3, -CH2C6~C 12 selected from aryl and C1-C6 alkyl; R 5 is -CH2C6~C 12 aryl or C1-C6 alkyl; R 6 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 aryl) Compound.

[0421] Embodiment P281.R 3 The compound according to embodiment P280, wherein is chloro.

[0422] Embodiment P282.R 3 The compound according to embodiment P280, wherein is bromo.

[0423] Embodiment P283.R 3 The compound according to embodiment P280, wherein is iodo.

[0424] Embodiment P284.R 4 -OR 6 and R 5 The compound according to embodiment P281, wherein is C1-C6 alkyl.

[0425] Embodiment P285.R 6 The compound according to embodiment P284, wherein is C1-C6 alkyl.

[0426] Embodiment P286. A compound according to Embodiment P285 wherein C1-C6 alkyl is tert-butyl.

[0427] Embodiment P287.R 5 The compound according to embodiment P286, wherein is tert-butyl.

[0428] Embodiment P288.R 4 -OR 6 and R 5 The compound according to embodiment P282, wherein is C1-C6 alkyl.

[0429] Embodiment P289.R 6 The compound according to embodiment P288, wherein is C1-C6 alkyl.

[0430] Embodiment P290. A compound according to embodiment P289 wherein C1-C6 alkyl is tert-butyl.

[0431] Embodiment P291.R 5The compound according to embodiment P290, wherein is tert-butyl.

[0432] Embodiment P292.R 4 -OR 6 and R 5 The compound according to embodiment P283, wherein is C1-C6 alkyl.

[0433] Embodiment P293.R 6 The compound according to embodiment P292, wherein is C1-C6 alkyl.

[0434] Embodiment P294. A compound according to embodiment P293, wherein C1-C6 alkyl is tert-butyl.

[0435] Embodiment P295.R 5 The compound according to embodiment P294, wherein is tert-butyl.

[0436] Embodiment P296. Formula (VIII) [ka] (In the formula: R 7 -OR 9 , -CF3, -CH2C6~C 12 aryl, and C1-C6 alkyl; R 8 is -CH2C6~C 12 aryl or C1-C6 alkyl; R 9 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 aryl) Compound.

[0437] Embodiment P297.R 7 -OR 9 and R 8 The compound according to embodiment P281, wherein is C1-C6 alkyl.

[0438] Embodiment P298.R 9 The compound according to embodiment P297, wherein is C1-C6 alkyl.

[0439] Embodiment P299. A compound according to embodiment P298, wherein C1-C6 alkyl is tert-butyl.

[0440] Embodiment P300.R 8 The compound according to embodiment P299, wherein is tert-butyl.

[0441] Embodiment P301. Formula (VIIIa) [ka] (In the formula: R 7 -OR 9 , -CF3, -CH2C6~C 12 aryl, and C1-C6 alkyl; R 8 is -CH2C6~C 12 aryl or C1-C6 alkyl; R 9 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 aryl) Compound.

[0442] Embodiment P302.R 7 -OR 9 and R 8 The compound according to embodiment P301, wherein is C1-C6 alkyl.

[0443] Embodiment P303.R 9 The compound according to embodiment P302, wherein is C1-C6 alkyl.

[0444] Embodiment P304. A compound according to embodiment P303 wherein C1-C6 alkyl is tert-butyl.

[0445] Embodiment P305.R 8The compound according to embodiment P304, wherein is tert-butyl.

[0446] Embodiment P306. Formula (VIIIb) [ka] (In the formula: R 7 -OR 9 , -CF3, -CH2C6~C 12 aryl, and C1-C6 alkyl; R 8 is -CH2C6~C 12 aryl or C1-C6 alkyl; R 9 is C1-C6 alkyl, C6-C 12 Aryl, and -CH2C6~C 12 aryl) Compound.

[0447] Embodiment P307.R 7 -OR 9 and R 8 The compound according to embodiment P306, wherein is C1-C6 alkyl.

[0448] Embodiment P308.R 9 The compound according to embodiment P307, wherein is C1-C6 alkyl.

[0449] Embodiment P309. A compound according to embodiment P308 wherein C1-C6 alkyl is tert-butyl.

[0450] Embodiment P310.R 8 The compound according to embodiment P309, wherein is tert-butyl. EXAMPLES

[0451] These examples are provided for illustrative purposes only and are not intended to limit the scope of the claims set forth herein.

[0452] Example 1: Preparation of 2-chloroethyl (2,5-dioxopyrrolidin-1-yl) carbonate [ka]

[0453] A 100 L jacketed reactor was equipped with an overhead stirrer, thermocouple probe and reflux condenser. About 750 grams of 2-chloroethyl chloroformate and about 15 liters of acetonitrile were added to the reactor. The resulting reaction mixture was cooled to 0° C. and stirred. About 786 grams (1.3 equivalents) of N-hydroxysuccinimide was added to the mixture, and then about 954 mL of triethylamine was added to the mixture over a period of 1 hour while maintaining the temperature of the mixture at or below 3° C. for a period of about 1 hour, after which time the reaction mixture was allowed to warm gradually to ambient temperature. Reaction progress was monitored using thin layer chromatography (TLC) using ethyl acetate / hexane (1 / 3 v / v) to develop the TLC plate, and iodine vapor and potassium permanganate stain were used for visualization. The reaction mixture was allowed to continue stirring until the presence of 2-chloroethyl chloroformate was no longer detected by TLC, after which time about 30 liters of deionized water was added, resulting in a clear solution. About 12 liters of ethyl acetate was then added to the reactor, and the resulting mixture was stirred. After stirring, the layers of the mixture were allowed to separate and the lower aqueous layer was removed and placed in a clean carboy, then the remaining organic layer was removed and placed in a clean carboy. The aqueous phase was returned to the reactor and another portion of ethyl acetate (approximately 12 liters) was added to the reactor and the resulting mixture was stirred and then the phases were allowed to separate. The lower aqueous phase was removed from the reactor and placed in a clean carboy, then the remaining organic phase was removed and placed in a clean carboy. This process was continued for 1 hour. 3 timesRepeat, then discard the remaining aqueous phase. Anhydrous magnesium sulfate was added to the organic layer, the mixture was stirred with a glass rod, and the solution was allowed to stand for 1 hour or more until the organic layer was deemed dry. The mixture was filtered through a medium porosity filter, and the remaining filter cake was washed with two volumes of ethyl acetate. The resulting mixture was concentrated under reduced pressure on a rotary evaporator (maximum bath temperature 60° C.) until no further distillate was observed, after which approximately 1.8 liters of hexane was added to the remaining residue to form a solid. The solid was then filtered through a medium porosity filter, and the remaining filter cake was washed with several volumes of hexane, and the remaining solid was then dried under reduced pressure to provide the title compound. 1 H NMR (500MHz, chloroform-d) δ 4.56(t,J=5.8, 5.8Hz,2H), 3.76(t,J=5.8, 5.8Hz,2H), 2.85(s,4H).

[0454] Example 2: 2 Preparation of -[(1,1-dimethylethoxy)carbonyl]-L-lysine 1,1-dimethylethyl ester (formula (Va)) [ka]

[0455] N 2 -[(1,1-dimethylethoxy)carbonyl]-N 6 -[(phenylmethoxy)carbonyl]-L-lysine A 100 L jacketed reactor was equipped with an overhead stirrer, thermocouple probe and reflux condenser. The reactor was purged with N 6 About 3.8 kilograms of -[(phenylmethoxy)carbonyl]-L-lysine, about 40 liters of deionized water, and about 2.05 kilograms (1.1 equivalents) of potassium carbonate were added. In a separate vessel, about 3.1 kilograms (1.05 equivalents) of di-tert-butyl dicarbonate and about 16 liters of 1,4-dioxane were added. The di-tert-butyl dicarbonate solution was then diluted with N 2 O while maintaining the temperature of the reaction mixture between about 20° C. and 25° C. 6-[(phenylmethoxy)carbonyl]-L-lysine was slowly added over 1 hour to the solution, and the resulting reaction mixture was cooled to 5°C with 6 The resulting mixture was stirred until it was determined that less than 1% -[(phenylmethoxy)carbonyl]-L-lysine material was present. The resulting mixture was concentrated under reduced pressure using a rotary evaporator with a bath temperature of about 45° C. to a volume of approximately 20 liters, after which approximately 7 liters of deionized water was added. The pH of the resulting mixture was then adjusted to a pH of approximately 3-4 by slowly adding 1N hydrochloric acid (approximately 22.4 liters). Approximately 20 liters of ethyl acetate was added to the resulting mixture, the mixture was stirred, the phases were allowed to separate, the aqueous phase was separated and poured into a clean container, and the remaining organic phase was poured into a clean container. The aqueous phase was returned to the reactor, an additional portion of ethyl acetate (approximately 20 liters) was added, the mixture was stirred, the phases were allowed to separate, and the aqueous and organic layers were separated. This process was repeated a second time, after which the aqueous phase was discarded. The combined organic phase was returned to the reactor, approximately 13 liters of 1N hydrochloric acid was added, the resulting mixture was stirred, the phases were allowed to separate, and the aqueous phase was removed and discarded. About 13 liters of deionized water was added to the remaining organic phase, the resulting mixture was agitated, the layers were allowed to separate, and the aqueous layer was separated and discarded. About 10 liters of saturated aqueous sodium chloride was added to the organic phase, the mixture was agitated, the phases were allowed to separate, and the lower aqueous phase was removed and discarded. Another portion of about 10 liters of sodium chloride was added, the mixture was agitated, the phases were allowed to separate, and the lower aqueous phase was removed and discarded. About 2 kilograms of anhydrous magnesium sulfate was added to the remaining organic phase, the mixture was agitated with a glass rod, and then allowed to settle for not less than one hour. The resulting mixture was filtered through a medium porosity filter, and the filter cake was washed with several volumes of ethyl acetate. The resulting solution was concentrated on a rotary evaporator under reduced pressure with a bath temperature of about 45° C. (maximum bath temperature 60° C.) until no further weight loss was observed, followed by addition of N 2 -[(1,1-dimethylethoxy)carbonyl]-N 6 -[(phenylmethoxy)carbonyl]-L-lysine was obtained as a solid. The resulting solid was dried in a vacuum oven at an oven temperature of about 50° C. with occasional agitation of the solid until the loss on drying was less than about 0.2% per hour.

[0456] N2 -[(1,1-dimethylethoxy)carbonyl]-N 6 -[(Phenylmethoxy)carbonyl]-L-lysine 1,1-dimethylethyl ester A 100 L jacketed reactor was equipped with an overhead stirrer, thermocouple probe and reflux condenser. The reactor was purged with N 2 -[(1,1-dimethylethoxy)carbonyl]-N 6 About 3.75 kilograms of -[(phenylmethoxy)carbonyl]-L-lysine and about 22 liters of tert-butanol were added. The resulting mixture was allowed to stir at a temperature of about 20° C. to about 23° C. until a clear solution was observed, after which about 2.85 kilograms (1.1 equivalents) of di-tert-butyl dicarbonate was added to the reactor and the resulting mixture was stirred at a temperature of about 20° C. to about 25° C. until a clear solution was obtained, followed by the addition of about 290 grams (0.2 equivalents) of 4-dimethylaminopyridine. The resulting mixture was stirred at a temperature of about 20° C. to about 24° C. for about 1.5 hours or more, and the reaction was continued in a 200 mL flask containing 100 mL of N 2 -[(1,1-dimethylethoxy)carbonyl]-N 6The reaction mixture was monitored until less than about 1% of -[(phenylmethoxy)carbonyl]-L-lysine remained, after which about 105 grams (0.1 equivalents) of 1,1-dimethyl-ethylenediamine was added and the resulting mixture was stirred at a temperature of about 20° C. for not less than 15 minutes. The reaction mixture was then cooled to a temperature of about −2° C. to about 3° C. and mixed with about 40 liters of 0.5 molar aqueous hydrochloric acid and about 20 liters of ethyl acetate, the resulting mixture was allowed to separate phases, and the aqueous and organic layers were separated and placed in clean containers. The aqueous phase was returned to the reactor and about 20 liters of ethyl acetate was added thereto, the mixture was stirred, the phases were allowed to separate, the aqueous phase was removed and discarded. The combined organic phase was returned to the reactor and about 20 liters of saturated sodium bicarbonate solution was added thereto, the resulting mixture was stirred, the phases were allowed to separate, the aqueous layer was removed and discarded. The organic phase was added with about 10 liters of aqueous sodium chloride solution, the mixture was stirred, the phases were allowed to separate, the aqueous phase was removed and discarded. About 2 kilograms of anhydrous magnesium sulfate was added to the organic layer, the mixture was stirred with a glass rod and then allowed to stand for at least 1 hour. The mixture was then filtered through a medium porosity filter, the filter cake was washed with several volumes of ethyl acetate, and the resulting solution was concentrated under reduced pressure using a rotary evaporator with a bath temperature of about 45° C. (maximum bath temperature of about 60° C.) until no further weight loss was observed, followed by elution with N 2 -[(1,1-dimethylethoxy)carbonyl]-N 6 -[(phenylmethoxy)carbonyl]-L-lysine 1,1-dimethylethyl ester was obtained as a solid. The resulting solid was dried in a vacuum oven at a temperature of about 50° C. with occasional stirring of the solid until the loss on drying was determined to be less than about 0.2% per hour.

[0457] N 2 -[(1,1-dimethylethoxy)carbonyl]-L-lysine 1,1-dimethylethyl ester (formula (Va)) A jacketed 100 liter stainless steel pressure reactor was equipped with an overhead mechanical stirrer and a hydrogen / nitrogen inlet. The reactor was charged with N 2 -[(1,1-dimethylethoxy)carbonyl]-N 6About 4360 grams of -[(phenylmethoxy)carbonyl]-L-lysine 1,1-dimethylethyl ester, about 600 grams of 10% palladium on carbon, and about 50 liters of tetrahydrofuran (THF) were added. The reactor was then pressurized with nitrogen in the range of about 20 psi to 40 psi and then depressurized. The nitrogen pressurization / depressurization process was repeated three times, after which the reactor was pressurized with hydrogen in the range of about 20 psi to 40 psi and then depressurized. After pressurizing the reactor with hydrogen at about 40 psi, the hydrogen pressurization / depressurization process was repeated three times. The reaction mixture was then heated to a temperature of about 40° C. to about 60° C. and stirred. N 2 -[(1,1-dimethylethoxy)carbonyl]-N 6 The progress of the reaction was monitored until less than about 1% -[(phenylmethoxy)carbonyl]-L-lysine 1,1-dimethylethyl ester reactant was present, after which the mixture was slowly cooled and maintained at a temperature of about 20° C.-25° C. for not less than 4 hours. The reactor was then depressurized, pressurized with nitrogen, and depressurized three times. The resulting mixture was filtered through a bed of Celite® slurried in THF using a medium porosity filter, and the resulting filter cake was washed with several volumes of THF. The resulting organic phases were combined and concentrated under reduced pressure using a rotary evaporator (maximum bath temperature 60° C.) until no further weight loss was observed, followed by addition of N 2 -[(1,1-dimethylethoxy)carbonyl]-L-lysine 1,1-dimethylethyl ester (formula (Va)) was obtained. 1 H NMR (500MHz, DMSO-d6) δ 7.06(d,J=7.7Hz,1H), 3.77~3.69(m,1H), 2.62(t,J=7.3, 7.3Hz,2H), 1.62~1.50(m,2H), 1.50~1.26(m,26H). Mass spectrum positive ionization mode: m / z 303.4(M+H).

[0458] Example 3: 2 Preparation of -[(1,1-dimethylethoxy)carbonyl]-L-lysine 1,1-dimethylethyl ester (formula (Va)) [ka]

[0459] A jacketed 100 L stainless steel pressure reactor was equipped with an overhead mechanical stirrer and a hydrogen gas dispersion tube. The reactor was filled with N 2 -[(1,1-dimethylethoxy)carbonyl]-N 6 About 4.53 kilograms of -[(phenylmethoxy)carbonyl]-L-lysine 1,1-dimethylethyl ester, about 15 liters of tetrahydrofuran (THF), about 15 liters of methanol, about 1.5 liters of glacial acetic acid, and about 1 kilogram of SiliaCat 10% palladium on carbon were added. The resulting mixture was stirred under nitrogen for about 15 minutes, after which hydrogen was added to the reactor, the temperature of the heating jacket was adjusted to a temperature of about 20° C. to about 25° C., and the resulting mixture was stirred until less than about 1% of the starting material remained. The resulting mixture was filtered through a medium porosity filter rinsing with tetrahydrofuran. The resulting solution was concentrated to a volume of about 6-7 liters using a rotary evaporator with a bath temperature of about 30° C., after which the remaining material was transferred to the reactor, followed by the addition of about 8 liters of methyl tert-butyl ether. About 13 liters of aqueous sodium bicarbonate was added to the solution, the mixture was stirred, and the phases were separated. The aqueous phase was washed with another portion of about 4 liters (×2) of methyl tert-butyl ether, the mixture was agitated, and the phases were separated. The organic layer was washed with about 4 liters of saturated aqueous sodium bicarbonate, and the layers were separated. The resulting organic layer was washed with about 4 liters of saturated aqueous sodium chloride solution, the layers were separated, and about 1 kilogram of anhydrous magnesium sulfate was added to the organic layer. The mixture was allowed to stand for about 1 hour, after which time it was filtered using a medium porosity filter, and the filter cake was washed with several portions of methyl tert-butyl ether. The resulting solution was concentrated using a rotary evaporator with a bath temperature of about 35° C., followed by 20 minutes of N 2 -[(1,1-dimethylethoxy)carbonyl]-L-lysine 1,1-dimethylethyl ester (Formula (Va)) was obtained as a solid. The solid was dried in a vacuum oven at an oven temperature of about 35° C. with occasional stirring until the loss on drying was determined to be less than about 0.2% per hour. 1H NMR (500MHz, DMSO-d6) δ 7.06(d,J=7.7Hz,1H), 3.77~3.69(m,1H), 2.62(t,J=7.3, 7.3Hz,2H), 1.62~1.50(m,2H), 1.50~1.26(m,26H). Mass spectrum positive ionization mode: m / z 303.4(M+H).

[0460] Example 4: tert-Butyl N 2 -(tert-butoxycarbonyl)-N 6 Preparation of -((2-chloroethoxy)carbonyl)-L-lysinate [ka]

[0461] A 100 L jacketed reactor was equipped with a reactor head, stirring assembly, stirring shaft, stirring paddle, Teflon coated thermocouple and overhead stirring and placed under a positive argon flow. The reactor was filled with N 2 About 2.9 kg of 1,1-dimethylethyl-L-lysine 1,1-dimethylethyl ester and about 19 liters of anhydrous N,N-dimethylformamide were added. The resulting mixture was cooled to 0°C-5°C with stirring, followed by the addition of about 1.5 liters of diisopropylethylamine. About 2.11 kg of solid 2-chloroethyl (2,5-dioxopyrrolidin-1-yl) carbonate was slowly added to the resulting mixture in portions, waiting about 10 minutes between the addition of each portion, while maintaining the internal temperature of the mixture at a temperature between 2°C-7°C. After complete addition of 2-chloroethyl (2,5-dioxopyrrolidin-1-yl) carbonate, the resulting mixture was allowed to stir for a minimum of 4 hours at a temperature between 2°C-7°C. 2The reaction progress was followed by determining by HPLC when the amount of -[(1,1-dimethylethoxy)carbonyl]-L-lysine 1,1-dimethylethyl ester was less than about 1%. The mixture was then cooled to a temperature between about -5°C and about 0°C, and 12 liters of heptane was added, followed by about 12 liters of ethyl acetate. About 30 liters of 0.5 molar aqueous hydrochloric acid solution was prepared in the vessel by adding about 28.75 liters of water and about 1.25 liters of concentrated hydrochloric acid to a separate vessel, which was then stirred and allowed to slowly cool to ambient temperature. About 30 liters of 0.5 molar aqueous hydrochloric acid solution was then added to the reaction mixture in the other vessel, the resulting mixture was stirred, the temperature was adjusted to between about 15°C and 25°C, and stirring was continued for about 15 minutes, after which stirring was stopped and the phases were allowed to separate. The aqueous layer was separated and placed in a separate vessel, which was then placed in a 50 liter reactor. About 2 liters of heptane and 2 liters of ethyl acetate were added to the aqueous layer, the resulting mixture was stirred for 10 minutes, and the layers were then allowed to separate. The aqueous layer was separated and placed in a separate vessel. This process was repeated. The combined organic layer was transferred from the 50 liter reactor to a 100 liter reactor along with the remaining organic layer from the first separation, then about 12 liters of water was added, the mixture was stirred for 15 minutes, and then the layers were allowed to separate. About 4 liters of saturated sodium chloride solution was added to the remaining organic layer, the mixture was stirred, the layers were allowed to separate, and the aqueous layer was removed. This process was repeated with a second portion of 4 liters of saturated sodium chloride solution. About 1.5 kg of anhydrous magnesium sulfate was added to the remaining organic layer, the mixture was stirred, and then filtered through a medium fritted funnel. The resulting solution was concentrated under reduced pressure using a rotary evaporator with the bath temperature set at 25° C. for this process, and a maximum bath temperature of 40° C., and polish filtered ethyl acetate was used to complete the transfer from the reactor to the rotary evaporator vessel. About 4 liters of acetonitrile was added to the remaining residue, which was then removed under reduced pressure using a rotary evaporator. A second portion of about 4 liters of acetonitrile was added and removed under reduced pressure using a rotary evaporator. The remaining residue was transferred to a drying tray and dried under reduced pressure in a vacuum oven set at a temperature of about 25°C.The solids in the drying trays are stirred occasionally and drying in a vacuum oven at about 25° C. is continued until the loss on drying is determined to be less than about 0.2% per hour, followed by drying with tert-butyl N. 2 -(tert-butoxycarbonyl)-N 6 -((2-chloroethoxy)carbonyl)-L-lysinate was obtained as a solid. 1 H NMR (500MHz, DMSO-d6) δ 7.24~7.16(m,1H), 7.02(d,J=7.6Hz,1H), 4.08(dd,J=5.7, 4.4Hz,2H), 3.76~3.69(m,1H), 3.50~3.44(m,2H), 2.94(h ,J=7.1, 7.1, 7.1, 7.1, 7.1Hz,2H), 1.63~1.47(m,3H), 1.37(d,J=2.2Hz,22H), 1.30~1.22(m,2H), 1.19~1.11(m,1H). Mass spectrum positive ionization mode: m / z 409.4(M+H).

[0462] Example 5: tert-Butyl N 6 -((2-azidoethoxy)carbonyl)-N 2 Preparation of -(tert-butoxycarbonyl)-L-lysinate (Formula (IIIa)) [ka]

[0463] A 100 liter jacketed reactor was equipped with a reactor head, stirring assembly, stirring shaft, stirring paddle, Teflon coated thermocouple and overhead stirring and placed under a positive argon flow. The reactor was charged with tert-butyl N 2 -(tert-butoxycarbonyl)-N 6 About 3.75 kg of 2-chloroethoxycarbonyl-L-lysinate and about 19 L of acetonitrile were added. A separate reaction vessel was charged with about 3 kg of sodium azide and about 19 L of water, and the contents were stirred until the solids were dissolved. The sodium azide solution was then added to tert-butyl N 2 -(tert-butoxycarbonyl)-N 6The resulting mixture was stirred and heated to a temperature of between about 70° C. and about 80° C., and stirring was continued for about 30 hours. The progress of the reaction was monitored by HPLC until less than about 1% tert-butyl N2-(tert-butoxycarbonyl)-N6-((2-chloroethoxy)carbonyl)-L-lysinate was determined to remain, after which the reaction mixture was slowly cooled to a temperature of between about 15° C. and 25° C., followed by the addition of about 12 liters of heptane and about 24 liters of ethyl acetate. The resulting mixture was stirred for about 15 minutes, the layers were allowed to separate, and the aqueous layer was removed and discarded. An additional portion of water (about 5 liters) was added to the remaining organic layer, the mixture was stirred, the layers were allowed to separate, and the aqueous layer was separated and discarded. This process was repeated using an additional portion of water (about 5 liters). Two liters of saturated sodium chloride solution was added to the organic layer, the resulting mixture was stirred for about 15 minutes, the layers were allowed to separate, and the aqueous layer was separated and discarded. This process was repeated using an additional portion (about 2 liters) of saturated sodium chloride solution. The remaining organic layer was filtered using a medium fritted funnel and the solvent was removed under reduced pressure using a rotary evaporator with a bath temperature of 25° C. and a maximum bath temperature of 40° C. The remaining solid was transferred to a drying tray and dried in a vacuum oven purged with argon and set at a temperature of 35° C. Drying was continued until the loss on drying was determined to be less than about 0.2% per hour, followed by drying for at least an additional 2 hours to obtain tert-butyl N 6 -((2-azidoethoxy)carbonyl)-N 2 -(tert-Butoxycarbonyl)-L-lysinate (Formula (IIIa)) was obtained as a solid. 1 H NMR (500MHz, DMSO-d6) δ 7.20(t,J=5.7, 5.7Hz,1H), 7.02(d,J=7.5Hz,1H), 4.15~4.05(m,2H), 3.72(td,J=8.3, 7.8, 5.1Hz,1 H), 3.50~3.45(m,2H), 3.01~2.89(m,2H), 1.60~1.49(m,2H), 1.44~1.24(m,25H), 1.19~1.12(m,1H). Mass spectrum positive ionization mode: m / z 416.7(M+H).

[0464] Example 6: N 6 Preparation of -((2-azidoethoxy)carbonyl)-L-lysine (formula (VIa)) [ka]

[0465] A 100 liter jacketed reactor was equipped with a reactor head, stirring assembly, stirring shaft, stirring paddle, Teflon coated thermocouple, overhead stirring, and a gas trap and placed under a positive argon flow. The reactor was charged with tert-butyl N 6 -((2-azidoethoxy)carbonyl)-N 2About 4.53 kg of -(tert-butoxycarbonyl)-L-lysinate (Formula (IIIa)) and 11 liters of 1,4-dioxane were added. The resulting mixture was stirred and cooled to a temperature between 5°C and 10°C. About 9.4 liters of concentrated hydrochloric acid was added to the mixture in 0.5 liter portions over a period of 2 hours to maintain the temperature of the reaction mixture between about 10°C and 15°C. After complete addition of the hydrochloric acid solution, the mixture was stirred and gradually warmed to a temperature between 42°C and 47°C, and stirring was continued at that temperature for about 3 hours. The reaction mixture was then cooled to a temperature between about 15°C and about 25°C, and then filtered through a medium fritted funnel into a separate container. About 6-7 liters of solvent was removed under reduced pressure using a rotary evaporator with a bath temperature of about 30°C and a maximum bath temperature of about 35°C. The remaining contents of the rotary evaporator were transferred to a jacketed reactor, stirred, and the temperature was adjusted to a temperature of about 15° C. to about 25° C. Between about 0.9 liters and 1.2 liters of aqueous ammonium hydroxide was slowly added to the reactor to maintain the internal temperature below 40° C. until a pH of between about 7 and 8 was achieved. The resulting suspension was cooled to a temperature of between about 5° C. to 10° C., after which time the solids were collected using a medium fritted funnel, rinsed with about 3 liters of water, and excess water was removed from the filter cake using a latex dam. The resulting solids were then transferred to a drying tray and dried in a vacuum oven under an argon purge with the oven temperature set at 35° C. The solids were continued to dry under reduced pressure with occasional stirring until the loss on drying was determined to be less than about 0.2% per hour, after which drying was continued for an additional 2 hours with N 6 -((2-azidoethoxy)carbonyl)-L-lysine (formula (VIa)) was obtained. 1 H NMR (500MHz, deuterium oxide) δ 4.12(t,J=4.8Hz,2H), 3.94(t,J=6.3Hz,1H), 3.43~3.37(m,2H), 3.04(t ,J=6.7Hz,2H), 1.93~1.75(m,2H), 1.49~1.38(m,2H), 1.38~1.26(m,2H). Mass spectrum positive ionization mode: m / z 260.3(M+H).

[0466] Example 7: Modified preparation of 2-chloroethyl (2,5-dioxopyrrolidin-1-yl) carbonate [ka]

[0467] The preparation of 2-chloroethyl (2,5-dioxopyrrolidin-1-yl) carbonate according to Example 1 was modified to facilitate industrial large-scale synthesis. In particular, modifications were made to reduce reaction and work-up volumes, and to replace drying of the organic phase with MgSO4 with azeo-distillation for drying. This was achieved, in part, by using 2-methyltetrahydrofuran (2-MeTHF) as the reaction solvent.

[0468] A 1 L jacketed three-neck reaction flask was equipped with overhead stirring, temperature control (TC), and an addition funnel (60 mL) with a nitrogen inlet to a bubbler. The flask was flushed with nitrogen and charged with 2-chloroethyl chloroformate (40.0 g, 0.280 mol), 2-Me-THF (512.8 g), and N-hydroxysuccinimide (41.9 g, 0.364 mol). The stirred mixture was cooled to -4°C. Triethylamine (36.8 g, 0.364 mol) was added slowly over 37 minutes while maintaining the temperature below 1°C. A thick precipitate formed during the addition. The temperature was adjusted to 11°C over 1 hour and the mixture was stirred at 11°C for 1 hour. The temperature was adjusted to 6°C and water (399 g) was added slowly over 16 minutes while maintaining the temperature below 10°C. All solids dissolved during the water addition to give a two liquid phase mixture. The mixture was stirred at 10-11 °C for 40 min. Stirring was stopped and the lower phase (aqueous) was removed. The water content of the organic phase was measured by KF (4.670%). The reaction flask was equipped for vacuum distillation: short path distillation head with receiver flask in acetone / dry ice bath, house vacuum equipped with bleed valve. Vacuum distillation was started. Jacket temperature was adjusted to 10-35 °C at the beginning of the distillation. The distillation was stopped when the pot volume was reduced to 200 mL. Pot temperature range during the distillation was 11-21 °C (KF of the cloudy pot solution was found to be 4.908%). 2-Me-THF (400 mL, 337.2 g) was then added to the pot. Solvent was distilled under reduced pressure vacuum until the pot volume was reduced to 200 mL. Pot temperature range during the distillation was 31-27 °C. A precipitate formed at the end of the distillation (KF of the pot supernatant was found to be 0.550%). The temperature was adjusted to 21° C. and the thin slurry was stirred for 30 minutes. n-Heptane (400 mL, 273.4 g) was added slowly over 10 minutes and the resulting slurry was stirred at 21° C. for 16 hours. The slurry was filtered (9 cm Buchner funnel, Whatman qualitative 1 paper) and rinsed forward with n-heptane (2×100 mL, 2×67 g). The wet cake was dried to constant weight (−30 inHg, 20° C., 1 hour) to give 56.12 g of the title compound as a solid (90.5%).

[0469] Example 8: tert-Butyl N 2 -(tert-butoxycarbonyl)-N 6 Alternative production of -((2-chloroethoxy)carbonyl)-L-lysinate [ka]

[0470] tert-Butyl N 2 -(tert-butoxycarbonyl)-N 6 The preparation of -((2-chloroethoxy)carbonyl)-L-lysinate was modified to facilitate industrial large-scale synthesis. This was achieved, in part, by using 2-MeTHF as the reaction solvent, followed by a solvent switch to acetonitrile and subsequent incorporation of the reaction into the next step.

[0471] A 500 mL jacketed three-neck reaction flask containing (S)-tert-butyl 6-amino-2-(tert-butoxycarbonylamino)hexanoate (Formula (Va)) (approximately 49.3 mmol) as a crude solution in 2-MeTHF was equipped with overhead stirring, TC, and an addition funnel (60 mL) with a nitrogen inlet to a bubbler. The stirred solution was cooled to 6° C. Then, 2-chloroethyl (2,5-dioxopyrrolidin-1-yl)carbonate (10.9 g, 49.2 mmol) was added in one portion resulting in a temperature rise to 14° C. The solution was cooled to 9° C. and diisopropylethylamine (DIPEA) (6.70 g, 51.8 mmol) was added via the addition funnel over 2 min, rinsing forward with 2-Me-THF (1.5 g). The jacket temperature was increased from 5° C. to 20° C. over 1 h. The temperature was adjusted to 18°C ​​and acetic acid solution (5 wt% in H2O, 90 g) was added slowly over 5 min while maintaining the temperature below 20°C. The mixture was stirred for 15 min at 20-22°C. The lower aqueous phase was removed and discarded (pH approx. 5, 102.6 g). The organic phase was stirred with Na2CO3 solution (5 wt% in H2O, 90 g) for 15 min. The lower aqueous phase was removed and discarded (pH approx. 10, 101.3 g). The organic phase was stirred with water (90 g) for 15 min. The lower aqueous phase was removed and discarded (pH 8-9, 104.1 g). The dark organic phase was polish filtered (0.2 μm Polycap PTFE membrane filter via FMI pump) rinsing forward with 2-Me-THF (2 x 42 g). Solvent was distilled under vacuum (jacket temperature 45° C.) until the pot volume was reduced to 100 mL (pot temperature range 44-32° C.). Acetonitrile (200 mL, 157.0 g) was added and solvent was distilled under vacuum (jacket temperature 45° C.) until the pot volume was reduced to 100 mL (pot temperature range 44-28° C.). The temperature was adjusted to 20° C. The solution containing the title compound was carried on directly to the next step.

[0472] Example 9: tert-Butyl N 6 -((2-azidoethoxy)carbonyl)-N 2 Alternative Preparation of -(tert-Butoxycarbonyl)-L-Lysinate (Formula (IIIa)) [ka]

[0473] tert-Butyl N 6 -((2-azidoethoxy)carbonyl)-N 2 The preparation of -(tert-butoxycarbonyl)-L-lysinate (Formula (IIIa)) was modified to facilitate industrial large-scale synthesis. This was achieved, in part, by replacing drying of the organic phase with MgSO4 with azeotropic distillation for drying.

[0474] tert-Butyl N as a crude solution in acetonitrile 2 -(tert-butoxycarbonyl)-N 6A 500 mL jacketed three-neck reaction flask containing -((2-chloroethoxy)carbonyl)-L-lysinate (approximately 20.1 g, 49.3 mmol) was equipped with overhead stirring, temperature control (TC), an addition funnel (60 mL), and a nitrogen inlet connected to a bubbler. The reactor jacket was set at 25 °C. Sodium azide (14.4 g, 220 mmol) was dissolved in deionized water (101 mL) at 25 °C in a 250 mL Erlenmeyer flask. The sodium azide solution was charged to the reactor in one portion, slightly endothermic (+1 °C). The jacket temperature was set at 80 °C. Once the internal temperature reached 75 °C, the reaction was stirred for not less than 20 hours (NLT). The reactor jacket was set at 25 °C. Ethyl acetate (120 mL) was charged to the reactor followed by n-heptane (60 mL). The reaction mixture was stirred at 25 °C for NLT 20 min. The phases were allowed to separate for NLT 15 min. The lower aqueous phase was removed and stored in a tared polypropylene bottle (119.1 g). The organic phase was added back to the reactor with H2O (30 mL). The mixture was stirred for NLT 20 min at 25° C. Then the phases were allowed to separate for NLT 15 min. The lower aqueous phase was removed and stored in a tared polypropylene bottle (36.3 g). The organic phase was added back to the reactor with H2O (30 mL) and the mixture was stirred for NLT 20 min at 25° C. The phases were allowed to separate for NLT 15 min. The lower aqueous phase was removed and stored in a tared polypropylene bottle (36.7 g). The organic phase was added back to the reactor with H2O (30 mL). The mixture was stirred for NLT 20 min at 25° C. Then the phases were allowed to separate for NLT 15 min. The lower aqueous phase was removed and stored in a tared polypropylene bottle (35.2 g). The organic phase was added back to the reactor with brine (17.9 g). The mixture was stirred for NLT 20 min at 25° C. The phases were allowed to separate for NLT 15 min. The lower aqueous phase was removed and stored in a tared polypropylene bottle (21.4 g). The organic phase was added back to the reactor with brine (17.9 g). The mixture was stirred for NLT 20 min at 25° C. The phases were allowed to separate for NLT 15 min. The lower aqueous phase was removed and stored in a tared polypropylene bottle (11.51 g). The organic phase was added back to the reactor and the jacket was set to 45° C. The solvent was then removed to approximately 100 mL.1,4-dioxane (200 mL, 207 g) was charged to the reactor and the solution was distilled again under vacuum to approximately 100 mL. The brown organic phase was polish filtered (0.2 μm Polycap PTFE membrane filter via FMI pump) and rinsed forward with 1,4-dioxane (2×103 g). The jacket was set to 65° C. and the solvent was removed to approximately 100 mL. The jacket was then set to 25° C. The 1,4-dioxane solution containing the title compound was carried directly to the next step.

[0475] Example 10. tert-Butyl N 6 -((2-azidoethoxy)carbonyl)-N 2 Accelerated rate calorimetry (ARC) study of -(tert-butoxycarbonyl)-L-lysinate (formula (IIIa)) N 6 -((2-azidoethoxy)carbonyl)-N 2 Accelerated rate calorimetry (ARC) studies were conducted to evaluate the safety of handling N-(tert-butoxycarbonyl)-L-lysinate (Formula (IIIa)). The ARC data were obtained using N 6 -((2-azidoethoxy)carbonyl)-N 2 This provides insight into the potential thermal hazards associated with the formation of -(tert-butoxycarbonyl)-L-lysinate (formula (IIIa)).

[0476] Purpose of the experiment The ARC test determines the onset of any self-accelerating exothermic activity and gas evolution in chemical systems under pseudoadiabatic conditions that typically occur during large-scale manufacturing and / or transportation. ARC uses the data to determine the enthalpy of reaction or decomposition and find the maximum temperature rise if cooling or stirring cannot be performed during critical processing steps.

[0477] A sample bomb (10 cm) connected at the top to a pressure transducer 3ARC tests were carried out in a 1000-KHz oven. The samples were sealed in an insulated bomb enclosure and the bomb enclosure was placed in the safety chamber of the apparatus. Thermocouples were placed in the bomb walls. The insulated enclosure consisted of two types of heaters: (i) radiant heaters used to heat the sample to its starting temperature and (ii) heaters used to control the adiabatic environment. Once heat output was detected from the sample, these heaters maintained the adiabatic environment by precisely matching the oven temperature to the sample temperature. A very accurate control system was used to detect very slight changes in the reaction mass temperature and thus the adiabatic control was very efficient. The calorimeter was housed in a robust chamber that could withstand the possible bomb rupture for materials that decompose or explode at extremely high rates.

[0478] result Tests were performed on the ARC in "heat-wait-search" (HWS) mode, which involved heating the sample in a fixed temperature step (e.g., 10°C) and allowing the sample to equilibrate at this temperature for a set period of time. The control system then searched for any slight temperature rise due to exothermic activity. A temperature rise of 0.02 K min-1 was detected throughout the entire search period. -1 If it was less than 0.02 K min, the cycle was repeated until exothermic activity was detected. -1 When a rate of temperature rise above 100°C was detected, the ARC control system switched to adiabatic mode, and the sample heater was then used to control the bomb's environment to the same temperature as the bomb itself.

[0479] N 6 -((2-azidoethoxy)carbonyl)-N 2 A sample of -(tert-butoxycarbonyl)-L-lysinate (Formula (IIIa)) was tested using HWS mode in an ARC under adiabatic conditions. The experimental parameters for the study are summarized in Table 1.

[0480] [Table 1]

[0481] Two self-heating events were observed during the test (Tables 2 and 3). The main exotherm started at an onset temperature of 160.5°C, leading to a pressure and temperature increase. The maximum self-heating rate recorded was 2.098 K / min at 211.5°C, while the maximum pressure rate was 2.756 bar / min at 208.5°C. The total heat content of the two exotherms was relatively small at 236.0 J / g. At approximately 380°C, the pressure reached a trip point set at 150 bar, which forced the experiment to be stopped before reaching the target final temperature of 400°C.

[0482] [Table 2]

[0483] [Table 3]

[0484] Plots of self-heating and pressure rate versus temperature are shown in Figure 1, and plots of temperature and pressure versus time are shown in Figure 2. The Antoine plot shown in Figure 3 shows that the pressure deviates from Antoine behavior at approximately 59.7°C, 227.2°C, 307.7°C, and 379.2°C. After completing the test and cooling to near ambient temperature of 30.7°C, 35.5 bar (gauge) of non-condensable gas remained in the bomb.

[0485] Time to reach maximum speed Test data obtained from the ARC can be used to estimate the self-accelerating decomposition temperature of a sample (J.K.Wilberforce, "The Use of the Accelerating Rate Calorimeter to determine the SADT of organic peroxides", Columbia Scientific Industries, Milton Keynes; Harold G.Fisher and David D.Goetz, "Determination of self-accelerating decomposition temperature using the accelerating rate calorimeter", J.Loss Prev. Process Ind., 1991, Vol. 4, 305-316). The time to maximum rate (TMR) is defined as the amount of time required for a reaction to reach its maximum self-heating rate or pressure rate in a thermal runaway reaction. The TMR data was extracted from the phi-factor corrected test data and a plot of Ln(TMR) versus -1000 / T was made (Figure 4).

[0486] The following equation was derived from Figure 4, allowing the determination of the time to reach maximum velocity as a function of temperature: Ln(TMR(sec))=-16.389*(-1000 / (T(K)))-29.262 The TMR increases as the batch temperature decreases. The measured heat release was used to estimate the TMR. The results are presented for reference only, as they are based on a single ARC test and not on a detailed kinetic study (Figure 5). The results for the time to maximum rate are summarized in Table 4.

[0487] [Table 4]

[0488] Data are from the reactions described herein. 6 -((2-azidoethoxy)carbonyl)-N 2It has been shown that there are no significant thermal hazards in the preparation of -(tert-butoxycarbonyl)-L-lysinate (Formula (IIIa)).

[0489] Example 11: N 6 Alternative Preparation of -((2-azidoethoxy)carbonyl)-L-lysine (Formula (VIa)) [ka]

[0490] N according to Example 6 6 The preparation of -((2-azidoethoxy)carbonyl)-L-lysine (Formula (VIa)) was modified to facilitate industrial large-scale synthesis. This was achieved, in part, by adjusting the pH of the solution to improve precipitation of the title compound.

[0491] tert-Butyl N as a crude solution in 1,4-dioxane 6 -((2-azidoethoxy)carbonyl)-N 2A 500 mL jacketed three-neck reaction flask containing -(tert-butoxycarbonyl)-L-lysinate (Formula (IIIa)) (approximately 20.4 g, 49.3 mmol) was equipped with overhead stirring, temperature control (TC), an addition funnel (60 mL), and a nitrogen inlet connected to a bubbler. The reactor jacket was set at 10°C. Once the temperature of the contents had stabilized at 10.3°C, concentrated hydrochloric acid (61.2 g, 51 mL, 220 mmol) was slowly charged to the reactor over 1 h. An exotherm of approximately +3 to +5°C was observed. The internal temperature was maintained below 20±5°C during the charge. Once the HCl charge was complete, the jacket temperature was increased to 45°C over 30 min. The solution was stirred at 45°C for not less than 3 h (NLT). The jacket was then ramped down from 45°C to 25°C over 1 h. The solution was polish filtered (0.2 μm Polycap PTFE membrane filter via FMI pump) and rinsed forward with 1,4-dioxane (2×103 g). The solution was charged back into the reactor and the jacket temperature was set to 60° C. The solution was stripped under vacuum to 5 V with the jacket at 60° C. The jacket temperature was then set to 10° C. With the contents temperature stable at 10.4° C., ammonium hydroxide (35 mL) was added slowly to the reactor over 1 hour. An exotherm of +5 to +15° C. could be observed based on the rate of addition. The temperature of the contents was kept below 25° C. As the addition of NH4OH proceeded, the solution turned into an off-white slurry. Ammonium hydroxide was added until the pH reached 8-9. Once the addition was complete, the jacket was set to 5° C. and the slurry was aged for 16 hours. The slurry was filtered through a "fine" fritted funnel. The wet cake was washed with HO (2×30 g) that was pre-cooled to 5° C. The solid was air-dried on a covered fritted funnel for 12 h, then dried under vacuum at 25° C. for 72 h to give the title compound as a solid (7.22 g, 57%).

[0492] Example 12. N in water 6 Effect of pH on the solubility of -((2-azidoethoxy)carbonyl)-L-lysine (formula (VIa)) N 6To further purify -((2-azidoethoxy)carbonyl)-L-lysine (formula (VIa)), 6 A suspension of -((2-azidoethoxy)carbonyl)-L-lysine (Formula (VIa)) was prepared, followed by the addition of HCl to form a solution. The resulting solution was neutralized with ammonium hydroxide to reprecipitate the product and further remove residual impurity material remaining in the solution. To improve the product yield, N 6 The effect of pH on the solubility of -((2-azidoethoxy)carbonyl)-L-lysine (Formula (VIa)) was investigated. Briefly, this study 6 -((2-azidoethoxy)carbonyl)-L-lysine (formula (VIa)) is suspended in water, the mixture is gradually basified, and the N 6 The amount of -((2-azidoethoxy)carbonyl)-L-lysine (formula (VIa)) was determined as a function of pH.

[0493] N 6 -((2-azidoethoxy)carbonyl)-L-lysine (formula (VIa)) (0.95 g) was placed in a 20 mL glass scintillation vial with water (7.2 g). The resulting suspension was mixed thoroughly on a vortex apparatus for 60 seconds and then allowed to settle for 5 minutes. The pH of the supernatant was measured to be 4.44 and an aliquot was taken and diluted with HPLC eluent (H2O:CH3CN 1:1, 0.1% TFA). The sample was analyzed by HPLC (column: ACE Excel 3 Super C18, 4.6 x 150 mm, 3.0 μm, flow rate: 1.2 mL / min, phase A: 0.1% TFA in water, phase B: 0.1% TFA in acetonitrile) and purified by N 6 The content of -((2-azidoethoxy)carbonyl)-L-lysine (Formula (VIa)) was calculated based on HPLC analysis of Formula (VIa) standard.

[0494] The contents of the scintillation vial were made basic by adding one drop of 28-30% ammonium hydroxide, the suspension was vortexed, decanted, and the supernatant was again sampled and analyzed by HPLC. This basification / analysis procedure was repeated five more times. The results are shown in Table 5.

[0495] [Table 5]

[0496] HPLC analysis showed that N 6 It has been shown that a saturated aqueous solution of -((2-azidoethoxy)carbonyl)-L-lysine (formula (VIa)) contains approximately the same amount of product in the supernatant. 6 Recovery of -((2-azidoethoxy)carbonyl)-L-lysine (Formula (VIa)) can be accomplished by precipitating the product in the pH range of 4 to 10, such as at a pH between about 7 to 8 or 8 to 9, or about 8 to 8.5.

[0497] Although preferred embodiments of the present disclosure have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the present disclosure. It should be understood that various alternatives to the disclosed embodiments described herein can be used in the practice of the present disclosure. It is intended that the following claims define the scope of the present disclosure, and that methods and structures within the scope of these claims and their equivalents are covered thereby. The disclosures of all patents and scientific literature cited herein are expressly incorporated herein by reference in their entirety. To the extent that any incorporated content does not contradict the explicit content of the present disclosure, the explicit content shall prevail.

Claims

1. Formula (VI) [Formula 1] or a salt thereof, comprising the steps of: To obtain a compound of formula (VI) or a salt thereof, [chemical 2] with an acid.

2. 2. The method of claim 1, wherein the acid is one or more of phosphoric acid, hydrochloric acid, acetic acid, and trifluoroacetic acid.

3. 3. The method according to claim 1 or 2, wherein the acid is hydrochloric acid.

4. 4. The process according to any one of claims 1 to 3, wherein the reaction of the compound of formula (III) with the acid is carried out in a solution comprising an aprotic solvent selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG 400 and polyethylene glycols.

5. The method of claim 4, wherein the aprotic solvent is 1,4-dioxane.

6. The process of any one of claims 1 to 5, further comprising the addition of a base.

7. 7. The method of claim 6, wherein the base is one or more of ammonium hydroxide, sodium hydroxide, or potassium hydroxide.

8. 8. The process of claim 6 or 7, wherein the base is ammonium hydroxide.

9. The method of any one of claims 6 to 8, wherein the addition of a base provides a solution having a pH in the range of 4 to 10.

10. A method according to any one of claims 6 to 9, wherein the addition of a base provides a solution having a pH in the range of 8 to 9.

11. The compound of formula (VI) has the formula (VIa) [C3] The method according to any one of claims 1 to 10, wherein the compound is

12. Formula (III) [C4] The method for preparing a compound of formula (II) to obtain a compound of formula (III) is provided. [C5] (In the formula, R 1 is selected from chloro, bromo, and iodo. with an alkali azide salt.

13. R 1 The method of claim 12, wherein is chloro.

14. 14. The method according to claim 12 or 13, wherein the alkali azide salt is selected from lithium azide, sodium azide, and potassium azide.

15. The method according to any one of claims 12 to 14, wherein the alkali azide salt is sodium azide.

16. 16. The method according to any one of claims 12 to 15, wherein the reaction of the compound of formula (II) with the alkali azide salt is carried out in a solution comprising an aprotic solvent selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG 400, polyethylene glycols.

17. 17. The method of claim 16, wherein the aprotic solvent is acetonitrile.

18. 18. The method of claim 16 or 17, wherein the solution further comprises water.

19. The compound of formula (III) has the formula (IIIa) [C6] and the compound of formula (II) is a compound of formula (IIa) [C7] The method according to any one of claims 12 to 18, wherein the compound is

20. Formula (II) [C8] The method for preparing a compound of formula (I) is provided by: [C9] With a compound of formula (V) [C10] with a compound of wherein in each of the compounds of formula (I) and formula (II), R 1 are the same and are selected from chloro, bromo and iodo.

21. R in each of the compounds of formula (I) and formula (II) 1 The method of claim 20, wherein is chloro.

22. 22. The method according to claim 20 or 21, wherein the reaction of the compound of formula (V) with the compound of formula (I) is carried out in a solution comprising an aprotic solvent selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG 400 and polyethylene glycols.

23. The method of claim 22, wherein the aprotic solvent is 2-methyltetrahydrofuran or N,N-dimethylformamide.

24. The compound of formula (II) has the formula (IIa) [C11] The compound of formula (V) is a compound of formula (Va): [C12] The method according to any one of claims 20 to 23, wherein the compound is

25. Formula (I) [C13] A process for preparing a compound of formula (I), comprising reacting a compound of formula (IV) [C14] with N-hydroxysuccinimide, wherein in each of the compounds of formula (I) and formula (IV), R 1 are the same and are selected from chloro, bromo, and iodo.

26. R 1 The method of claim 25, wherein is chloro.

27. 27. The method according to claim 25 or 26, wherein the reaction of the compound of formula (IV) with N-hydroxysuccinimide is carried out in a solution comprising an aprotic solvent selected from acetonitrile, acetone, methyl ethyl ketone, dichloromethane, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran, N-methylpyrrolidine, dimethylsulfoxide, N,N-dimethylformamide, dimethylacetamide, 1,4-dioxane, sulfolane, gamma butyrolactone, pyrrolidones, 1-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG 400 and polyethylene glycols.

28. The method of claim 27, wherein the aprotic solvent is acetonitrile or 2-methyltetrahydrofuran.

29. 29. The method of claim 27 or 28, wherein the solution further comprises a base.

30. 30. The method of claim 29, wherein the base is a trialkylamine.

31. 31. The method of claim 29 or 30, wherein the base is triethylamine.

32. A method for preparing a compound of formula (VIa), or a salt thereof, comprising the steps of: (i) [C15] To form [C16] of [C17] and reacting with (ii) [C18] To form [C19] of [C20] and reacting with (iii) [C21] To form [C22] to NaN 3 and reacting with (iv) [C23] or to form a salt thereof [C24] with HCl; The method comprising:

33. Formula (I): [C25] (In the formula, R 1 is selected from chloro, bromo, and iodo. Compound.

34. R 1 The compound of claim 33, wherein is chloro.

35. Formula (II): [C26] (In the formula, R 1 is selected from chloro, bromo, and iodo. Compound.

36. R 1 The compound of claim 35, wherein is chloro.

37. The compound of formula (II) has the formula (IIa): [C27] 37. The compound according to claim 35 or 36, which is a compound of the formula:

38. Formula (III): [C28] Compound.

39. The compound of formula (III) has the formula (IIIa): [C29] 39. The compound of claim 38, which is a compound of the formula:

40. Formula (VII): [C30] (In the formula: R 3 is selected from chloro, bromo and iodo; R 4 is -OR 6 , -CF 3 , -CH 2 C 6 ~C 12 Aryl, and C 1 ~C 6 alkyl; R 5 is -CH 2 C 6 ~C 12 Aryl or C 1 ~C 6 is alkyl; R 6 is C 1 ~C 6 Alkyl, C 6 ~C 12 Aryl, and -CH 2 C 6 ~C 12 aryl) Compound.

41. Formula (VIII): [C31] (In the formula: R 7 is -OR 9 , -CF 3 , -CH 2 C 6 ~C 12 Aryl, and C 1 ~C 6 alkyl; R 8 is -CH 2 C 6 ~C 12 Aryl or C 1 ~C 6 is alkyl; R 9 is C 1 ~C 6 Alkyl, C 6 ~C 12 Aryl, and -CH 2 C 6 ~C 12 aryl) Compound.

Citation Information

Patent Citations

  • Universal synthesis method for fluorine-containing non-natural lysine derivative

    CN108997168A

  • amino acid derivative

    JP2016534099A

  • Adeno-Associated Virus with Site-Directed Mutagenesis and Site-Directed Modification and Preparation Method and Application Thereof

    US20160297855A1

  • Hepatitis c inhibitor compounds

    WO2012019299A1